MICHEL Constance

Constance.michel@univ-amu.fr
Phone : +33491324807

Cardiovascular (CVS) imaging team.

I2M

MSK

Platform

Platform Engineer at Carnot STAR Institute

Coordination of the transversal program of muscle segmentation and preclinical research in musculoskeletal pathological models in the MSK team.

Engineer dedicated to preclinical experimentations, image processing and segmentations for the CVS, I2M and MSK team.

Engineer

Post-doctoral Fellow (PhD)

Detailed Activities

My research activity is focused on the non-invasive investigation of skeletal muscle function and energetics under normal and pathological conditions. I use innovative home-build devices developed for longitudinal investigation of anatomy, mechanical performance, energy metabolism in exercising muscle in vivo mainly using multimodal MR techniques (functional and anatomic MRI, dynamic 31P-MRS) in murine models. More specifically, a part of my work is dedicated to the evaluation of therapeutics strategies (Hydroxyurea and GBT1118) with or without endurance training on the skeletal muscle function and energetics in a murine model of sickle cell disease (Townes mice).

I’m also involved in the management of a transversal program of segmentation. The musculoskeletal group developed an nnUNet automated tool dedicated to the fast segmentation of individual muscle in order to extract quantitative data (volume, fat fraction, T2 values and MTR) allowing the investigation of normal and pathological skeletal muscle anatomy and physiology. In this project, I specialize in the tool operation (images preparations, segmentations, qMRI extractions, statistics) and management where I work in collaboration with clinicians for the study of various pathologies (CMT, FSH, IBM, DMD).

I also apply my skills to the CVS and I2M team in order to perform and facilitate preclinical experiments and processing.

Keywords

  • Dynamic MRI/MRS, Quantitative MRI/MRS
  • Skeletal muscle function & energetics
  • Preclinical studies
  • Clinical studies
  • Segmentation tool

Publications :

180164 MICHEL 1 harvard-cite-them-right-no-et-al 50 date desc year 2863 https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EBKNBNNG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20A.%2C%20Leray%2C%20E.%2C%20Marignier%2C%20R.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Mathey%2C%20G.%2C%20Michel%2C%20L.%2C%20De%20Seze%2C%20J.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.A.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Moreau%2C%20T.%2C%20Berger%2C%20E.%2C%20Dubessy%2C%20A.-L.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al%20Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanche%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Moulin%2C%20S.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Dos%20Santos%2C%20A.%2C%20Pottier%2C%20C.%2C%20Manchon%2C%20E.%2C%20Tchikviladze%2C%20M.%2C%20Lebrun-Frenay%2C%20C.%2C%20Vukusic%2C%20S.%20and%20OFSEP%20investigators%20%282025%29%20%26%23x201C%3BSex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20105%284%29%2C%20p.%20e213907.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20the%20therapeutic%20strategy%20may%20be%20influenced%20by%20the%20anticipation%20of%20future%20pregnancies%2C%20leading%20to%20underexposure%20to%20disease-modifying%20therapies%20%28DMTs%29%20and%20highly%20effective%20DMTs%20%28HEDMTs%29%20compared%20with%20men.%20We%20aimed%20to%20evaluate%20potential%20therapeutic%20inertia%20in%20women%20with%20MS%20and%20explore%20its%20causes.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20based%20on%20data%20extracted%20on%20June%202023%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20for%20all%20patients%20with%20a%20relapsing-remitting%20MS%20onset%20between%2018%20and%2040%20years.%20The%20primary%20outcome%20was%20the%20annual%20probability%20of%20receiving%20a%20DMT%2C%20accounting%20for%20sex%2C%20disease%20severity%2C%20and%20pregnancy%5C%2Fpostpartum%20periods.%20Secondary%20outcomes%20were%20the%20annual%20probability%20of%20receiving%20a%20HEDMT%2C%20each%20DMT%20separately%2C%20and%20interaction%20of%20the%20effect%20of%20sex%20with%20calendar%20year%2C%20patient%20age%2C%20and%20disease%20duration.%20We%20used%20a%20longitudinal%20logistic%20model%20with%20generalized%20estimating%20equations%20and%20an%20inverse-probability-of-censoring%20weighting.%5CnRESULTS%3A%20We%20included%2022%2C657%20patients%20with%20MS%3B%2016%2C857%20%2874.4%25%29%20were%20female%2C%20mean%20%28SD%29%20age%20at%20onset%20was%2029.0%20%286.0%29%20years%2C%20and%20median%20%28interquartile%20range%29%20follow-up%20duration%20was%2011.6%20%286.6-17.3%29%20years.%20Women%20were%20significantly%20less%20likely%20to%20receive%20a%20DMT%20%28odds%20ratio%20%5BOR%5D%200.92%2C%2095%25%20CI%200.87-0.97%29%20or%20a%20HEDMT%20%28OR%200.80%2C%2095%25%20CI%200.74-0.86%29.%20This%20difference%20appeared%202%20years%20after%20disease%20onset%20for%20DMTs%20and%201%20year%20for%20HEDMTs%2C%20and%20did%20not%20differ%20significantly%20according%20to%20patient%26%23039%3Bs%20age.%20Teriflunomide%2C%20sphingosine-1-phosphate%20receptor%20modulators%2C%20and%20anti-CD20s%20were%20significantly%20underused%20in%20women%20throughout%20their%20entire%20period%20of%20availability%3B%20interferons%20%5Cu03b2%20%28IFN-%5Cu03b2%29%20and%20natalizumab%20were%20initially%20less%20used%20and%20then%20equally%20after%20some%20time%3B%20glatiramer%20acetate%20and%20fumarates%20were%20first%20used%20equally%2C%20then%20more%20frequently%20in%20women.%20The%20proportion%20of%20treated%20women%2C%20analyzed%20from%20the%20first%20childbirth%20of%205%2C268%20women%2C%20began%20to%20decline%2018%20months%20before%20childbirth%2C%20from%2042.6%25%20to%2027.9%25%20at%20the%20estimated%20time%20of%20conception.%5CnDISCUSSION%3A%20Women%20with%20MS%20were%20significantly%20less%20exposed%20to%20DMTs%20compared%20with%20men.%20Anticipation%20of%20pregnancy%20was%20probably%20an%20important%20factor%20underlying%20this%20difference%2C%20but%20also%20sex-specific%20therapeutic%20inertia.%20Neurologists%20and%20patients%20should%20be%20educated%20on%20the%20most%20recent%20recommendations%20on%20the%20use%20of%20DMTs%20in%20the%20context%20of%20pregnancy%20to%20avoid%20deleterious%20therapeutic%20inertia.%22%2C%22date%22%3A%222025-08-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213907%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22T4W95BS2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robin%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRobin%2C%20C.%2C%20Rollot%2C%20F.%2C%20Lefort%2C%20M.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20De%20Seze%2C%20J.%2C%20Stankoff%2C%20B.%2C%20Maillart%2C%20E.%2C%20Ruet%2C%20A.%2C%20Labauge%2C%20P.M.%2C%20Kwiatkowski%2C%20A.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Moulin%2C%20S.%2C%20Camdessanche%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Sarov%2C%20M.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Dos%20Santos%2C%20A.%2C%20Manchon%2C%20E.%2C%20Tchikviladze%2C%20M.%2C%20Nifle%2C%20C.%2C%20Kerbrat%2C%20A.%2C%20Edan%2C%20G.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%20and%20as%20the%20OFSEP%20Investigators%20%282025%29%20%26%23x201C%3BUse%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20105%283%29%2C%20p.%20e213744.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20The%20therapeutic%20strategy%20in%20patients%20with%20late-onset%20MS%20%28LOMS%29%20remains%20poorly%20defined.%20In%20this%20study%2C%20we%20aimed%20to%20evaluate%20both%20clinical%20and%20MRI%20outcomes%20between%202%20cohorts%20of%20patients%20with%20relapsing-remitting%20LOMS%20treated%20or%20not%20yet%20treated.%5CnMETHODS%3A%20Patients%20with%20relapsing-remitting%20MS%20were%20included%20for%20the%20analysis%20if%20disease%20onset%20occurred%20after%2055%20years%20and%20if%20they%20had%20at%20least%20one%20follow-up%20visit.%20The%20primary%20outcome%20was%20time%20to%20first%20relapse%20between%202%20matched%20groups%20of%20patients%20with%20LOMS%20%28treated%20and%20not%20yet%20treated%29.%20Secondary%20outcomes%20were%20as%20follows%3A%20%281%29%20time%20to%20first%20confirmed%20disability%20progression%20%28CDP%29%2C%20%282%29%20time%20to%20first%20progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20event%2C%20%283%29%20time%20to%20secondary%20progression%20%28SPMS%29%2C%20%284%29%20time%20to%20first%20MRI%20activity%2C%20and%20%285%29%20serious%20infection%20incidence%20rates%20%28IIRs%29.%20For%20the%20comparative%20analyses%2C%20we%20adopted%20a%20time-dependent%20propensity%20score%20matching%20approach.%5CnRESULTS%3A%20A%20total%20of%20881%20patients%20fulfilled%20the%20inclusion%20criteria.%20The%20mean%20%28SD%29%20age%20at%20onset%20was%2059.9%20%284.43%29%20years.%20After%20applying%20propensity%20score%20matching%2C%20436%20patients%20were%20matched.%20The%20mean%20%28SD%29%20follow-up%20duration%20was%205.2%20%284.27%29%20years%20in%20the%20treated%20group%20and%205.0%20%283.86%29%20years%20in%20the%20not-yet-treated%20group.%20Mean%20%28SD%29%20time%20to%20first%20relapse%20was%20significantly%20longer%20in%20the%20treated%20group%20compared%20with%20the%20not-yet-treated%20group%20%287.0%20years%20%5B0.33%5D%20vs%205.4%20years%20%5B0.33%5D%3B%20p%20%3D%200.001%29.%20Mean%20%28SD%29%20time%20to%20first%20MRI%20activity%20was%20significantly%20longer%20in%20the%20treated%20group%20%285.9%20years%20%5B0.33%5D%20vs%205.0%20years%20%5B0.33%5D%3B%20p%20%3D%200.049%29.%20However%2C%20the%20mean%20time%20to%20CDP%2C%20PIRA%2C%20or%20SPMS%20was%20not%20different%20between%20the%202%20groups%20%28difference%20%3D%200.32%20years%3B%20p%20%3D%200.585%20for%20CDP%3B%20difference%20%3D%200.40%20years%3B%20p%20%3D%200.442%20for%20PIRA%3B%20difference%20%3D%20-0.02%20years%3B%20p%20%3D%200.952%20for%20SPMS%29.%20No%20increase%20in%20serious%20IIRs%20was%20observed%20with%20an%20incidence%20rate%20ratio%20of%200.38%20%2895%25%20CI%200.07-2.10%2C%20p%20%3D%200.265%29%20in%20the%20never-treated%20group%20compared%20with%20the%20treated%20one.%5CnDISCUSSION%3A%20This%20study%20demonstrates%20a%20beneficial%20effect%20of%20disease-modifying%20therapy%20%28DMT%29%20on%20disease%20activity%20in%20patients%20with%20LOMS%20but%20without%20significant%20impact%20on%20disability%20progression.%20Main%20limitations%20are%20linked%20to%20the%20challenge%20of%20data%20collection%20and%20to%20the%20baseline%20imbalances%20between%20the%202%20groups.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20in%20patients%20with%20LOMS%2C%20treatment%20with%20DMTs%20is%20associated%20with%20a%20longer%20time%20to%20first%20relapse%20compared%20with%20those%20not%20treated%20with%20DMTs.%22%2C%22date%22%3A%222025-08-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213744%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22NCYFCF6W%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hong%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHong%2C%20J.%2C%20Gaubert%2C%20M.%2C%20Lefort%2C%20M.%2C%20Ferr%26%23xE9%3B%2C%20J.C.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%2C%20Labauge%2C%20P.%2C%20Pelletier%2C%20J.%2C%20de%20Seze%2C%20J.%2C%20Durand-Dubief%2C%20F.%2C%20Cotton%2C%20F.%2C%20Edan%2C%20G.%2C%20Bannier%2C%20E.%2C%20Comb%26%23xE8%3Bs%2C%20B.%20and%20Kerbrat%2C%20A.%20%282025%29%20%26%23x201C%3BLimited%20added%20value%20of%20systematic%20spinal%20cord%20MRI%20vs%20brain%20MRI%20alone%20to%20classify%20patients%20with%20MS%20as%20active%20or%20inactive%20during%20follow-up%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20272%284%29%2C%20p.%20316.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20added%20value%20of%20systematic%20spinal%20cord%20MRI%20vs%20brain%20MRI%20alone%20to%20classify%20patients%20with%20MS%20as%20active%20or%20inactive%20during%20follow-up%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malo%22%2C%22lastName%22%3A%22Gaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Ferr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Comb%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20utility%20of%20systematic%20spinal%20cord%20%28SC%29%20MRI%20for%20monitoring%20disease%20activity%20after%20a%20multiple%20sclerosis%20%28MS%29%20diagnosis%20remains%20a%20topic%20of%20debate.%5CnOBJECTIVES%3A%20To%20evaluate%20the%20frequency%20of%20disease%20activity%20when%20considering%20brain%20MRI%20alone%20versus%20both%20brain%20and%20SC%20MRI%20and%20to%20identify%20factors%20associated%20with%20the%20occurrence%20of%20new%20SC%20lesions.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20analysis%20of%20clinical%20and%20imaging%20data%20prospectively%20collected%20over%205%5Cu00a0years%20as%20part%20of%20the%20EMISEP%20cohort%20study.%20A%20total%20of%20221%20intervals%20%28with%20both%20brain%20and%20spinal%20cord%20MRI%20scans%20available%20at%202%20consecutive%20time-points%29%20from%2068%20patients%20were%20analysed.%20For%20each%20interval%2C%20brain%20%283D%20Fluid-Attenuated%20Inversion%20Recovery%20%28FLAIR%2C%20axial%20T2%20and%20axial%20PD%29%20and%20SC%20MRI%20%28sagittal%20T2%20and%20phase-sensitive%20inversion%20recovery%2C%20axial%20T2%2Aw%20and%203D%20T1%29%20were%20reviewed%20to%20detect%20new%20lesions.%20Each%20interval%20was%20classified%20as%20symptomatic%20%28with%20relapse%29%20or%20asymptomatic.%20The%20baseline%20brain%20and%20SC%20lesion%20numbers%20were%20computed.%5CnRESULTS%3A%20SC%20MRI%20activity%20without%20clinical%20relapse%20and%5C%2For%20brain%20MRI%20activity%20was%20rare%20%284%20out%20of%20221%20intervals%2C%202%25%29.%20The%20occurrence%20of%20a%20new%20SC%20lesion%20was%20associated%20with%20the%20number%20of%20brain%20lesions%20at%20baseline%20%28OR%20%3D%5Cu20091.002%20%5B1.000%3B%201.0004%5D%2C%20p%5Cu2009%3D%200.015%29%20and%20the%20occurrence%20of%20a%20new%20brain%20lesion%20during%20the%20interval%20%28OR%20%3D%5Cu20091.170%20%5B1.041%3B%201.314%5D%2C%20p%5Cu2009%3D%200.009%29%2C%20but%20not%20with%20the%20baseline%20SC%20lesion%20number%20%28p%5Cu2009%3D%200.6%29.%5CnCONCLUSION%3A%20These%20findings%20support%20the%20current%20guidelines%20recommending%20routine%20disease%20monitoring%20with%20brain%20MRI%20alone%2C%20even%20in%20patients%20with%20a%20high%20SC%20lesion%20load.%22%2C%22date%22%3A%222025-04-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00415-025-13068-2%22%2C%22ISSN%22%3A%221432-1459%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22ZA2SCPEV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mainguy%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMainguy%2C%20M.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Lebrun-Frenay%2C%20C.%2C%20Berger%2C%20E.%2C%20Kerbrat%2C%20A.%2C%20Al%20Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Ciron%2C%20J.%2C%20Clavelou%2C%20P.%2C%20De%20Seze%2C%20J.%2C%20Defer%2C%20G.%2C%20Doghri%2C%20I.%2C%20Dos%20Santos%2C%20A.%2C%20Hankiewicz%2C%20K.%2C%20Labauge%2C%20P.M.%2C%20Le%20Page%2C%20E.%2C%20Magy%2C%20L.%2C%20Maillart%2C%20E.%2C%20Manchon%2C%20E.%2C%20Michel%2C%20L.%2C%20Moreau%2C%20T.%2C%20Moulin%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Pottier%2C%20C.%2C%20Ruet%2C%20A.%2C%20Sarov%2C%20M.%2C%20Stankoff%2C%20B.%2C%20Thouvenot%2C%20E.%2C%20Wahab%2C%20A.%2C%20Zephir%2C%20H.%2C%20Leray%2C%20E.%20and%20Laplaud%2C%20D.A.%20%282025%29%20%26%23x201C%3BAssessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%282%29%2C%20p.%20e200371.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Mainguy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Older%20studies%20reported%20an%20increased%20risk%20of%20relapse%20after%20in%20vitro%20fertilization%20%28IVF%29%20in%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20which%20has%20not%20been%20confirmed%20by%20more%20recent%20works.%20All%20these%20studies%20had%20several%20limitations%2C%20such%20as%20small%20sample%20sizes%2C%20absence%20of%20a%20control%20population%2C%20or%20lack%20of%20neurologic%20validation%20of%20the%20relapses.%20The%20aim%20of%20this%20study%20was%20to%20determine%20the%20risk%20of%20relapse%20after%20IVF%20in%20women%20with%20MS.%5CnMETHODS%3A%20This%20retrospective%20cohort%20study%20included%20all%20women%20with%20MS%20who%20underwent%20IVF%20between%202009%20and%202019%20and%20a%20control%20group%20of%20women%20with%20MS%20who%20did%20not%20undergo%20IVF%20matched%20on%20age%2C%20MS%20duration%2C%20number%20of%20relapses%2C%20and%20MS-specific%20treatments%20in%20the%20previous%20year.%20Data%20on%20MS%20%28disease%20duration%2C%20treatments%2C%20and%20relapses%29%20were%20from%20the%20French%20MS%20Registry%20%28OFSEP%29%2C%20whereas%20data%20on%20IVF%20%28number%20of%20procedures%2C%20stimulation%20protocol%20type%2C%20and%20outcomes%29%20were%20from%20the%20French%20national%20health%20insurance%20database.%20For%20this%2C%20the%202%20databases%20were%20linked%20by%20indirect%20matching.%5CnRESULTS%3A%20In%20total%2C%20115%20women%20with%20MS%20underwent%20199%20IVF%20procedures%20%28mean%20age%20at%20first%20IVF%3A%2033.9%20%5Cu00b1%204.0%20years%3B%2045.2%25%20had%20%5Cu22652%20IVF%20procedures%29%2C%20and%20175%20IVFs%20%2888.0%25%29%20could%20be%20matched%20to%20specific%20patients.%20The%20risk%20of%20relapse%20in%20the%203%20months%20after%20index%20date%20was%20the%20same%20in%20both%20IVF%20group%20and%20control%20group%20%280.06%20relapse%20per%20patient-year%29%2C%20as%20confirmed%20also%20by%20the%20before-after%20analysis%20in%20the%20IVF%20group%20%280.06%20vs%200.08%29.%5CnDISCUSSION%3A%20This%20study%2C%20using%20a%2010-year%20clinical%20and%20administrative%20dataset%2C%20did%20not%20find%20any%20increased%20risk%20of%20relapse%20after%20IVF.%20The%20maintenance%20of%20disease-modifying%20therapies%20until%20IVF%20was%20a%20determining%20factor%20in%20reducing%20the%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200371%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22MKSZ2T58%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20S%5Cu00e8ze%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3Bde%20S%26%23xE8%3Bze%2C%20J.%2C%20Labauge%2C%20P.%2C%20Liblau%2C%20R.%2C%20Martinez%2C%20M.%2C%20Moreau%2C%20T.%2C%20Suchet%2C%20L.%2C%20Vermersch%2C%20P.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Michel%2C%20L.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Cohen%2C%20M.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Giannesini%2C%20C.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Neau%2C%20J.-P.%2C%20Pottier%2C%20C.%2C%20Dobay%2C%20P.%2C%20Li%2C%20H.%2C%20Levin%2C%20S.%2C%20Gros%2C%20M.%2C%20Ruiz%2C%20M.%20and%20Rollot%2C%20F.%20%282025%29%20%26%23x201C%3BLymphoTEC%3A%20a%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAdvances%20in%20Therapy%26lt%3B%5C%2Fi%26gt%3B%20%5BPreprint%5D.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LymphoTEC%3A%20a%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roland%22%2C%22lastName%22%3A%22Liblau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Suchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%22%2C%22lastName%22%3A%22Dobay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanyue%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%22%2C%22lastName%22%3A%22Levin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marilyn%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dimethyl%20fumarate%20%28DMF%29%20has%20demonstrated%20a%20favorable%20benefit-risk%20profile%20in%20patients%20with%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29.%20Some%20patients%20may%20develop%20lymphopenia%20on%20DMF%3B%20therefore%2C%20LymphoTEC%20evaluated%20absolute%20lymphocyte%20count%20%28ALC%29%20reconstitution%20after%20DMF%20discontinuation.%5CnMETHODS%3A%20LymphoTEC%20was%20a%20retrospective%2C%20multicenter%20study%20of%20patients%20with%20RRMS%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20registry.%20Times%20to%20ALC%20reconstitution%20and%20lymphopenia%20were%20estimated%20by%20the%20Kaplan-Meier%20method.%20Univariate%20and%20multivariate%20analyses%20evaluated%20factors%20associated%20with%20ALC%20reconstitution%20after%20DMF%20discontinuation%20or%20lymphopenia%20after%20DMF%20initiation.%20Patients%20treated%20with%20DMF%20for%5Cu00a0%5Cu2265%5Cu00a03%5Cu00a0months%20with%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20in%20the%206%5Cu00a0months%20before%5C%2Fclose%20to%20DMF%20initiation%20and%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20during%20treatment%20were%20included.%5CnRESULTS%3A%20Overall%2C%201429%20RRMS%20patients%20were%20included%3B%20356%20patients%20developed%20lymphopenia%2C%20of%20whom%20183%20discontinued%20DMF.%20Overall%2C%20ALC%20decreased%20by%2033%25%20over%20the%20first%20year%20and%20plateaued%20thereafter.%20The%20probability%20of%20developing%20lymphopenia%20was%2018.2%25%20after%201%5Cu00a0year.%20In%20patients%20with%20lymphopenia%2C%20median%20times%20to%20ALC%20reconstitution%20after%20DMF%20discontinuation%20were%203.8%5Cu00a0months%20overall%2C%204.0%5Cu00a0months%20for%20Grade%201%20lymphopenia%2C%203.0%5Cu00a0months%20for%20Grade%202%2C%20and%209.7%5Cu00a0months%20for%20Grade%203.%20At%2012%5Cu00a0months%2C%2083.0%25%20had%20reconstituted%20ALC.%20In%20DMF%20discontinuers%2C%20median%20time%20to%20discontinuation%20was%201.2%5Cu00a0years.%20There%20was%20no%20increased%20risk%20of%20serious%20or%20opportunistic%20infections%20in%20patients%20with%20lymphopenia.%20No%20cases%20of%20progressive%20multifocal%20leukoencephalopathy%20were%20reported.%20First%20ALC%20reconstitution%20after%20DMF%20discontinuation%20was%20associated%20with%20diabetes%2C%20DMF%20duration%2C%20DMF%20duration%20before%20lymphopenia%2C%20and%20DMF%20duration%20after%20lymphopenia%3B%20first%20lymphopenia%20after%20DMF%20initiation%20was%20associated%20with%20age%20and%20ALC%20at%20DMF%20initiation.%5CnCONCLUSION%3A%20LymphoTEC%20confirms%20previous%20reports%20on%20DMF-induced%20lymphopenia%3B%20the%20benefit-risk%20profile%20of%20DMF%20remains%20favorable.%20Most%20cases%20of%20lymphopenia%20were%20not%20severe%20and%20ALC%20reconstitution%20typically%20occurred%20within%204%5Cu00a0months%20of%20DMF%20discontinuation.%20Patients%20with%20shorter%20and%20milder%20lymphopenia%20had%20faster%20ALC%20reconstitution.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20NCT04756687.%22%2C%22date%22%3A%222025-02-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs12325-024-03092-5%22%2C%22ISSN%22%3A%221865-8652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22PY4E2DQ4%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martin%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartin%2C%20S.%2C%20Andr%26%23xE9%3B%2C%20R.%2C%20Trabelsi%2C%20A.%2C%20Michel%2C%20C.P.%2C%20Fortanier%2C%20E.%2C%20Attarian%2C%20S.%2C%20Guye%2C%20M.%2C%20Dubois%2C%20M.%2C%20Abdeddaim%2C%20R.%20and%20Bendahan%2C%20D.%20%282025%29%20%26%23x201C%3BImportance%20of%20neural%20network%20complexity%20for%20the%20automatic%20segmentation%20of%20individual%20thigh%20muscles%20in%20MRI%20images%20from%20patients%20with%20neuromuscular%20diseases%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagma%20%28New%20York%2C%20N.Y.%29%26lt%3B%5C%2Fi%26gt%3B%20%5BPreprint%5D.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-024-01221-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-024-01221-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Importance%20of%20neural%20network%20complexity%20for%20the%20automatic%20segmentation%20of%20individual%20thigh%20muscles%20in%20MRI%20images%20from%20patients%20with%20neuromuscular%20diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amira%22%2C%22lastName%22%3A%22Trabelsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Redha%22%2C%22lastName%22%3A%22Abdeddaim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Segmentation%20of%20individual%20thigh%20muscles%20in%20MRI%20images%20is%20essential%20for%20monitoring%20neuromuscular%20diseases%20and%20quantifying%20relevant%20biomarkers%20such%20as%20fat%20fraction%20%28FF%29.%20Deep%20learning%20approaches%20such%20as%20U-Net%20have%20demonstrated%20effectiveness%20in%20this%20field.%20However%2C%20the%20impact%20of%20reducing%20neural%20network%20complexity%20remains%20unexplored%20in%20the%20FF%20quantification%20in%20individual%20muscles.%5CnMATERIAL%20AND%20METHODS%3A%20U-Net%20architectures%20with%20different%20complexities%20have%20been%20compared%20for%20the%20quantification%20of%20the%20fat%20fraction%20in%20each%20muscle%20group%20selected%20in%20the%20central%20part%20of%20the%20thigh%20region.%20The%20corresponding%20performance%20has%20been%20assessed%20in%20terms%20of%20Dice%20score%20%28DSC%29%20and%20FF%20quantification%20error.%20The%20database%20contained%201450%20thigh%20images%20from%2059%20patients%20and%2014%20healthy%20subjects%20%28age%3A%2047%5Cu2009%5Cu00b1%5Cu200917%5Cu00a0years%2C%20sex%3A%2036F%2C%2037M%29.%20Ten%20individual%20muscles%20were%20segmented%20in%20each%20image.%20The%20performance%20of%20each%20model%20was%20compared%20to%20nnU-Net%2C%20a%20complex%20architecture%20with%204.35%20%5Cu00d7%20107%20parameters%2C%2012.8%20Gigabytes%20of%20peak%20memory%20usage%20and%20167%5Cu00a0h%20of%20training%20time.%5CnRESULTS%3A%20As%20expected%2C%20nnU-Net%20achieved%20the%20highest%20DSC%20%2894.77%5Cu2009%5Cu00b1%5Cu20090.13%25%29.%20A%20simpler%20U-Net%20%285.81%20%5Cu00d7%20105%20parameters%2C%202.37%20Gigabytes%2C%2014%5Cu00a0h%20of%20training%20time%29%20achieved%20a%20lower%20DSC%20but%20still%20above%2090%25.%20Surprisingly%2C%20both%20models%20achieved%20a%20comparable%20FF%20estimation.%5CnDISCUSSION%3A%20The%20poor%20correlation%20between%20observed%20DSC%20and%20FF%20indicates%20that%20less%20complex%20architectures%2C%20reducing%20GPU%20memory%20utilization%20and%20training%20time%2C%20can%20still%20accurately%20quantify%20FF.%22%2C%22date%22%3A%222025-01-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10334-024-01221-3%22%2C%22ISSN%22%3A%221352-8661%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%22ZP8JD3DQ%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22MXAE4SPT%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Comino%20Garcia%20Mu%5Cu00f1oz%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BComino%20Garcia%20Mu%26%23xF1%3Boz%2C%20A.%2C%20Marfouk%2C%20O.%2C%20Michel%2C%20C.P.%2C%20Varlet%2C%20I.%2C%20Royer%2C%20E.%2C%20Perles-Barbacaru%2C%20T.-A.%20and%20Viola%2C%20A.%20%282025%29%20%26%23x201C%3BCharacterization%20of%20experimental%20cerebral%20malaria%20by%20volumetric%20MRI%20A%20comparative%20study%20across%20the%20sexes%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2C%2020%288%29%2C%20p.%20e0328693.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0328693%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0328693%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characterization%20of%20experimental%20cerebral%20malaria%20by%20volumetric%20MRI%20A%20comparative%20study%20across%20the%20sexes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Comino%20Garcia%20Mu%5Cu00f1oz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oumaima%22%2C%22lastName%22%3A%22Marfouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Royer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teodora-Adriana%22%2C%22lastName%22%3A%22Perles-Barbacaru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e8le%22%2C%22lastName%22%3A%22Viola%22%7D%5D%2C%22abstractNote%22%3A%22Cerebral%20malaria%20%28CM%29%2C%20a%20potentially%20lethal%20neurological%20complication%20of%20the%20infection%20by%20Plasmodium%20falciparum%2C%20affects%20mostly%20the%20pediatric%20population%20under%205%20years%20old%20in%20sub-Saharan%20Africa.%20This%20clinical%20syndrome%20is%20characterized%20on%20anatomical%20brain%20imaging%20by%20microhemorrhages%2C%20parenchymal%20lesions%20and%20brain%20edema.%20Epidemiological%20studies%20based%20on%20sex%20or%20gender%20are%20rare%20and%20do%20not%20allow%20to%20draw%20any%20conclusions%20on%20a%20possible%20sexual%20dimorphism%20in%20CM.%20However%2C%20some%20regional%20data%20and%20genetic%20studies%20suggest%20a%20possible%20influence%20of%20sex%20on%20the%20susceptibility%20to%20this%20clinical%20syndrome%20and%20complications%20in%20surviving%20patients.%20The%20murine%20model%20of%20experimental%20cerebral%20malaria%20%28ECM%29%20in%20mice%20has%20proven%20to%20be%20a%20useful%20and%20reliable%20tool%20to%20study%20the%20pathogenic%20mechanisms%20and%20possible%20therapeutical%20approaches%20for%20CM.%20In%20this%20study%2C%20we%20used%20in%20vivo%20magnetic%20resonance%20imaging%20%28MRI%29%20to%20assess%20the%20differences%20linked%20to%20sex%20in%20the%20development%20of%20experimental%20CM%20in%20C57BL%5C%2F6J%20mice%20infected%20with%20the%20murine%20parasite%20Plasmodium%20berghei%20ANKA.%20Our%20volumetric%20analysis%20reveals%20sex-dependent%20differences%20in%20brain%20swelling%20and%20lesion%20distribution%2C%20particularly%20microhemorrhages%2C%20as%20well%20as%20a%20regionalization%20of%20brain%20edema%20in%20ECM%2C%20with%20swelling-prone%20structures%20common%20to%20both%20sexes%20like%20the%20cortex%20and%20the%20pons%2C%20and%20others%20which%20show%20sex-specific%20alterations%20like%20the%20inferior%20and%20superior%20colliculi%20or%20the%20midbrain.%20Together%2C%20our%20results%20indicate%20that%20ECM%20is%20more%20severe%20in%20male%20than%20in%20female%20C57Bl%5C%2F6J%20mice.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0328693%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJ2IN35K%22%2C%22QUDUANE7%22%2C%22ZP8JD3DQ%22%2C%22K2ZDD9C7%22%2C%22E2YLML4H%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22FYSDR7HI%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fortanier%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFortanier%2C%20E.%2C%20Michel%2C%20C.P.%2C%20Hostin%2C%20M.A.%2C%20Delmont%2C%20E.%2C%20Verschueren%2C%20A.%2C%20Guye%2C%20M.%2C%20Bellemare%2C%20M.-E.%2C%20Bendahan%2C%20D.%20and%20Attarian%2C%20S.%20%282025%29%20%26%23x201C%3BQuantitative%20muscle%20MRI%20combined%20with%20AI-based%20segmentation%20as%20a%20follow-up%20biomarker%20for%20ATTRv%20patients%3A%20A%20longitudinal%20pilot%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2032%281%29%2C%20p.%20e16574.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16574%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16574%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quantitative%20muscle%20MRI%20combined%20with%20AI-based%20segmentation%20as%20a%20follow-up%20biomarker%20for%20ATTRv%20patients%3A%20A%20longitudinal%20pilot%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20Adrien%22%2C%22lastName%22%3A%22Hostin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Verschueren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Emmanuel%22%2C%22lastName%22%3A%22Bellemare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Objectives%20Intramuscular%20fat%20fraction%20%28FF%29%2C%20assessed%20using%20quantitative%20MRI%20%28qMRI%29%2C%20has%20emerged%20as%20a%20promising%20biomarker%20for%20hereditary%20transthyretin%20amyloidosis%20%28ATTRv%29%20patients.%20Currently%2C%20the%20main%20drawbacks%20to%20its%20use%20in%20future%20therapeutic%20trials%20are%20its%20sensitivity%20to%20change%20over%20a%20short%20period%20of%20time%20and%20the%20time-consuming%20manual%20segmentation%20step%20to%20extract%20quantitative%20data.%20This%20pilot%20study%20aimed%20to%20demonstrate%20the%20suitability%20of%20an%20Artificial%20Intelligence-based%20%28AI%29%20segmentation%20technique%20to%20assess%20disease%20progression%20in%20a%20real-life%20cohort%20of%20ATTRv%20patients%20over%201%20year.%20Methods%20Fifteen%20ATTRv%20patients%20were%20included%20in%20this%20monocentric%2C%20observational%2C%20prospective%20study.%20FF%2C%20magnetization%20transfer%20ratio%20%28MTR%29%2C%20and%20quantitative%20T2%20were%20extracted%20from%20patients%26%23039%3B%20lower%20limb%20qMRI%20at%20two%20time%20points%2C%201%20year%20apart%2C%20at%20thigh%20and%20leg%20levels.%20qMRI%20parameters%20were%20correlated%20with%20clinical%20and%20electrophysiological%20parameters%20assessed%20at%20the%20same%20time.%20Results%20Global%20FF%20at%20leg%20level%20significantly%20progressed%20over%201%20year%3A%20%2B1.28%20%5Cu00b1%202.62%25%20%28p%20%3D%200.017%29.%20At%20thigh%20level%2C%20no%20significant%20change%20in%20global%20FF%2C%20MTR%2C%20or%20T2%20was%20measured.%20The%20leg%20FF%20was%20strongly%20correlated%20with%20the%20main%20clinical%20and%20electrophysiological%20scores.%20Conclusion%20AI-based%20CNN%20network%20segmentation%20combined%20with%20qMRI%20can%20be%20used%20to%20obtain%20quantitative%20metrics%20for%20longitudinal%20studies%20in%20ATTRv%20patients.%20Global%20FF%20at%20the%20leg%20level%20seems%20to%20be%20the%20most%20sensitive%20MRI%20biomarker%20to%20track%20disease%20progression%20in%20a%201-year%20period.%20Larger%20studies%20with%20treatment-specific%20groups%20will%20now%20be%20necessary%20to%20determine%20the%20place%20of%20qMRI%20markers%20compared%20to%20the%20current%20clinical%20and%20electrophysiological%20scores.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16574%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fene.16574%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22G9U7ZF6L%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cruz%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCruz%2C%20E.S.%2C%20Fortanier%2C%20E.%2C%20Michel%2C%20C.P.%2C%20Delmont%2C%20E.%2C%20Verschueren%2C%20A.%2C%20Hostin%2C%20M.-A.%2C%20Bendahan%2C%20D.%20and%20Attarian%2C%20S.%20%282025%29%20%26%23x201C%3BIntraepineurial%20Fat%20Fraction%3A%20A%20Novel%20MR%20Neurography-Based%20Biomarker%20in%20Transthyretin%20Amyloidosis%20Polyneuropathy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2032%284%29.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.70168%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.70168%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intraepineurial%20Fat%20Fraction%3A%20A%20Novel%20MR%20Neurography-Based%20Biomarker%20in%20Transthyretin%20Amyloidosis%20Polyneuropathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Sole%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Verschueren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Adrien%22%2C%22lastName%22%3A%22Hostin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.70168%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Famu.hal.science%5C%2Fhal-05264578%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222025-09-19T07%3A43%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22TVTUEVRR%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hay%20et%20al.%22%2C%22parsedDate%22%3A%222024-10-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHay%2C%20M.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Kerbrat%2C%20A.%2C%20Edan%2C%20G.%2C%20Mathey%2C%20G.%2C%20Labauge%2C%20P.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Laplaud%2C%20D.-A.%2C%20Papeix%2C%20C.%2C%20Moreau%2C%20T.%2C%20Thouvenot%2C%20E.%2C%20Defer%2C%20G.%2C%20Lebrun-Fr%26%23xE9%3Bnay%2C%20C.%2C%20Ciron%2C%20J.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Maillart%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Ruet%2C%20A.%2C%20Casez%2C%20O.%2C%20Moulin%2C%20S.%2C%20Al-Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Pelletier%2C%20J.%2C%20Magy%2C%20L.%2C%20Neau%2C%20J.-P.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Wahab%2C%20A.%2C%20Tchikviladz%26%23xE9%3B%2C%20M.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%20and%20as%20the%20OFSEP%20Investigators%20%282024%29%20%26%23x201C%3BAnti-CD20%20Therapies%20in%20Drug-Naive%20Patients%20With%20Primary%20Progressive%20Multiple%20Sclerosis%3A%20A%20Multicenter%20Real-Life%20Study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20103%288%29%2C%20p.%20e209886.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209886%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209886%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-CD20%20Therapies%20in%20Drug-Naive%20Patients%20With%20Primary%20Progressive%20Multiple%20Sclerosis%3A%20A%20Multicenter%20Real-Life%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Fr%5Cu00e9nay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maia%22%2C%22lastName%22%3A%22Tchikviladz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Although%20rituximab%20failed%20to%20demonstrate%20a%20significant%20effect%20on%20disability%20progression%20in%20primary%20progressive%20multiple%20sclerosis%20%28PPMS%29%2C%20ocrelizumab%20succeeded.%20Our%20main%20objective%20was%20to%20analyze%20confirmed%20disability%20progression%20%28CDP%29%20in%20a%20cohort%20of%20patients%20with%20PPMS%20treated%20with%20anti-CD20%20therapies%20compared%20with%20a%20weighted%20untreated%20control%20cohort.%5CnMETHODS%3A%20This%20was%20a%20retrospective%20study%20using%20data%20from%20the%20French%20MS%20registry%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20En%20Plaques%29.%20We%20included%20patients%20with%20PPMS%20treated%20or%20never%20treated%20with%20anti-CD20%20therapies%20from%202016%20to%202021%2C%20with%20an%20Expanded%20Disability%20Status%20Scale%20score%20of%20%5Cu22646.5%20at%20baseline.%20The%20primary%20outcome%20was%20time%20to%20first%20CDP.%20The%20secondary%20outcomes%20were%20time%20to%20first%20relapse%2C%20MRI%20activity%20at%202%20years%2C%20identification%20of%20risk%20factors%20associated%20with%20CDP%2C%20and%20serious%20infection%20incidence%20rates%20%28IIRs%29.%20Each%20outcome%20was%20studied%20using%20an%20inverse%20probability%20of%20treatment%20weighting%20method.%20The%20outcomes%20were%20modeled%20using%20a%20weighted%20proportional%20Cox%20model%20for%20the%20time-to-event%20outcomes%20and%20by%20a%20logistic%20regression%20regarding%20the%20MRI%20activity.%5CnRESULTS%3A%20A%20total%20of%201%2C184%20patients%20%28426%20treated%20and%20758%20untreated%29%20fulfilled%20the%20inclusion%20criteria.%20Median%20age%20%28Q1-Q3%29%20was%2056%20years%20%2849.3-63.8%29%2C%20and%2052.7%25%20were%20female.%20Among%20treated%20patients%2C%20295%20received%20rituximab%2C%20whereas%20131%20received%20ocrelizumab.%20At%20baseline%2C%20anti-CD20-treated%20patients%20were%20younger%20%28median%2051.9%20vs%2058.6%20years%2C%20Cohen%20d%20%3D%200.683%29%20and%20had%20more%20active%20disease%20%2854.5%20vs%2027.8%25%2C%20Cohen%20d%20%3D%200.562%29.%2091.6%25%20were%20drug-naive%20at%20inclusion.%20In%20time%20to%20first%20CDP%20analysis%2C%20no%20statistical%20significance%20was%20observed%20%28hazard%20ratio%20%5BHR%5D%2C%201.13%3B%2095%25%20CI%200.93-1.36%2C%20p%20%3D%200.2113%29.%20In%20time%20to%20first%20relapse%20analysis%2C%20a%20nonsignificant%20trend%20toward%20fewer%20patients%20relapsing%20in%20the%20treated%20group%20was%20observed%20%28HR%200.83%3B%2095%25%20CI%200.48-1.28%2C%20p%20%3D%200.0809%29.%20For%20MRI%20activity%2C%20no%20significant%20difference%20was%20found%20between%20the%202%20groups.%20Risk%20factors%20associated%20with%20CDP%20in%20the%20treated%20group%20were%20male%20sex%20and%20MS%20duration.%20IIR%20was%206.67%20%2895%25%20CI%203.12-14.25%29%20per%20100%20person-years%20in%20the%20treated%20group%20vs%202.67%20%2895%25%20CI%200.80-8.86%29%20in%20the%20untreated%20group.%5CnDISCUSSION%3A%20Time%20to%20first%20CDP%20was%20not%20different%20between%20anti-CD20%20treated%20and%20untreated%20patients%20with%20PPMS.%20Although%20our%20study%20is%20retrospective%20and%20mainly%20included%20patients%20treated%20by%20rituximab%2C%20our%20results%20indicate%20that%20there%20should%20be%20a%20constant%20evaluation%20of%20all%20available%20data%20to%20ascertain%20the%20best%20risk%5C%2Fbenefit%20ratio%20for%20patients%20with%20PPMS.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20anti-CD20%20therapy%20of%20previously%20untreated%20patients%20with%20PPMS%20was%20not%20superior%20to%20no%20therapy%20in%20delaying%20time%20to%20first%20CDP.%22%2C%22date%22%3A%222024-10-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209886%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22VLBWEWJY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fortanier%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFortanier%2C%20E.%2C%20Hostin%2C%20M.A.%2C%20Michel%2C%20C.%2C%20Delmont%2C%20E.%2C%20Bellemare%2C%20M.-E.%2C%20Guye%2C%20M.%2C%20Bendahan%2C%20D.%20and%20Attarian%2C%20S.%20%282024%29%20%26%23x201C%3BOne-Year%20Longitudinal%20Assessment%20of%20Patients%20With%20CMT1A%20Using%20Quantitative%20MRI%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20102%289%29%2C%20p.%20e209277.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209277%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209277%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22One-Year%20Longitudinal%20Assessment%20of%20Patients%20With%20CMT1A%20Using%20Quantitative%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20Adrien%22%2C%22lastName%22%3A%22Hostin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Emmanuel%22%2C%22lastName%22%3A%22Bellemare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Objectives%5CnIntramuscular%20fat%20fraction%20%28FF%29%20assessed%20using%20quantitative%20MRI%20%28qMRI%29%20has%20emerged%20as%20one%20of%20the%20few%20responsive%20outcome%20measures%20in%20CMT1A%20suitable%20for%20future%20clinical%20trials.%20This%20study%20aimed%20to%20identify%20the%20relevance%20of%20multiple%20qMRI%20biomarkers%20for%20tracking%20longitudinal%20changes%20in%20CMT1A%20and%20to%20assess%20correlations%20between%20MRI%20metrics%20and%20clinical%20parameters.%5CnMethods%5CnqMRI%20was%20performed%20in%20CMT1A%20patients%20at%202%20time%20points%2C%20a%20year%20apart%2C%20and%20various%20metrics%20were%20extracted%20from%203-dimensional%20volumes%20of%20interest%20at%20thigh%20and%20leg%20levels.%20A%20semiautomated%20segmentation%20technique%20was%20used%2C%20enabling%20the%20analysis%20of%20central%20slices%20and%20a%20larger%203D%20muscle%20volume.%20Metrics%20included%20proton%20density%20%28PD%29%2C%20magnetization%20transfer%20ratio%20%28MTR%29%2C%20and%20intramuscular%20FF.%20The%20sciatic%20and%20tibial%20nerves%20were%20also%20assessed.%20Disease%20severity%20was%20gauged%20using%20Charcot%20Marie%20Tooth%20Neurologic%20Score%20%28CMTNSv2%29%2C%20Charcot%20Marie%20Tooth%20Examination%20Score%2C%20Overall%20Neuropathy%20Limitation%20Scale%20scores%2C%20and%20Medical%20Research%20Council%20%28MRC%29%20muscle%20strength.%5CnResults%5CnTwenty-four%20patients%20were%20included.%20FF%20significantly%20rose%20in%20the%203D%20volume%20at%20both%20thigh%20%28%2B1.04%25%20%5Cu00b1%202.19%25%2C%20p%20%3D%200.041%29%20and%20leg%20%28%2B1.36%25%20%5Cu00b1%201.87%25%2C%20p%20%3D%200.045%29%20levels.%20The%203D%20analyses%20unveiled%20a%20length-dependent%20gradient%20in%20FF%2C%20ranging%20from%2022.61%25%20%5Cu00b1%2010.17%25%20to%2026.17%25%20%5Cu00b1%2010.79%25%20at%20the%20leg%20level.%20There%20was%20noticeable%20variance%20in%20longitudinal%20changes%20between%20muscles%3A%20%2B3.17%25%20%5Cu00b1%206.86%25%20%28p%20%3D%200.028%29%20in%20the%20tibialis%20anterior%20compared%20with%200.37%25%20%5Cu00b1%204.97%25%20%28p%20%3D%200.893%29%20in%20the%20gastrocnemius%20medialis.%20MTR%20across%20the%20entire%20thigh%20volume%20showed%20a%20significant%20decline%20between%20the%202%20time%20points%20%5Cu22122.75%20%5Cu00b1%206.58%20%28p%20%3D%200.049%29%2C%20whereas%20no%20significant%20differences%20were%20noted%20for%20the%203D%20muscle%20volume%20and%20PD.%20No%20longitudinal%20changes%20were%20observed%20in%20any%20nerve%20metric.%20Potent%20correlations%20were%20identified%20between%20FF%20and%20primary%20clinical%20measures%3A%20CMTNSv2%20%28%5Cu03c1%20%3D%200.656%3B%20p%20%3D%200.001%29%20and%20MRC%20in%20the%20lower%20limbs%20%28%5Cu03c1%20%3D%20%5Cu22120.877%3B%20p%20%26lt%3B%200.001%29.%5CnDiscussion%5CnOur%20results%20further%20support%20that%20qMRI%20is%20a%20promising%20tool%20for%20following%20up%20longitudinal%20changes%20in%20CMT1A%20patients%2C%20FF%20being%20the%20paramount%20MRI%20metric%20for%20both%20thigh%20and%20leg%20regions.%20It%20is%20crucial%20to%20scrutinize%20the%20postimaging%20data%20extraction%20methods%20considering%20that%20annual%20changes%20are%20minimal%20%28around%20%2B1.5%25%29.%20Given%20the%20varied%20FF%20distribution%2C%20the%20existence%20of%20a%20length-dependent%20gradient%2C%20and%20the%20differential%20fatty%20involution%20across%20muscles%2C%203D%20volume%20analysis%20appeared%20more%20suitable%20than%20single%20slice%20analysis.%22%2C%22date%22%3A%222024-05-14%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209277%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.neurology.org%5C%2Fdoi%5C%2F10.1212%5C%2FWNL.0000000000209277%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%22ZP8JD3DQ%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22E9LICJTQ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Monestier%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMonestier%2C%20L.%2C%20Del%20Grande%2C%20J.%2C%20Haddad%2C%20R.%2C%20Santini%2C%20L.%2C%20Michel%2C%20J.%2C%20Varoquaux%2C%20A.%20and%20Fakhry%2C%20N.%20%282024%29%20%26%23x201C%3BCorrelation%20between%20MRI%20%28DWI%20and%20DCE%29%20and%20cellularity%20of%20parotid%20gland%20pleomorphic%20adenomas%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Archives%20of%20Oto-Rhino-Laryngology%26lt%3B%5C%2Fi%26gt%3B%2C%20281%285%29%2C%20pp.%202655%26%23x2013%3B2665.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00405-024-08562-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00405-024-08562-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correlation%20between%20MRI%20%28DWI%20and%20DCE%29%20and%20cellularity%20of%20parotid%20gland%20pleomorphic%20adenomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Monestier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Del%20Grande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Santini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justin%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Varoquaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Fakhry%22%7D%5D%2C%22abstractNote%22%3A%22Parotid%20pleomorphic%20adenomas%20present%20a%20risk%20of%20recurrence%2C%20higher%20when%20the%20tumour%20is%20a%20hypocellular%20subtype.%20The%20aim%20of%20the%20study%20was%20to%20determine%20whether%20it%20is%20possible%20to%20characterize%20this%20histological%20subtype%20with%20diffusion%20and%20perfusion%20sequences%20of%20the%20preoperative%20MRI.%22%2C%22date%22%3A%222024-05-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00405-024-08562-8%22%2C%22ISSN%22%3A%221434-4726%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00405-024-08562-8%22%2C%22collections%22%3A%5B%22KBIRKXGV%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22S2J8WZ96%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Michel%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMichel%2C%20C.P.%2C%20Messonnier%2C%20L.A.%2C%20Giannesini%2C%20B.%2C%20Vilmen%2C%20C.%2C%20Sourdon%2C%20J.%2C%20Le%20Fur%2C%20Y.%20and%20Bendahan%2C%20D.%20%282024%29%20%26%23x201C%3BEndurance%20training%20and%20hydroxyurea%20have%20synergistic%20effects%20on%20muscle%20function%20and%20energetics%20in%20sickle%20cell%20disease%20mice%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BBlood%20Cells%2C%20Molecules%20%26amp%3B%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%20107%2C%20p.%20102853.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bcmd.2024.102853%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bcmd.2024.102853%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Endurance%20training%20and%20hydroxyurea%20have%20synergistic%20effects%20on%20muscle%20function%20and%20energetics%20in%20sickle%20cell%20disease%20mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20A.%22%2C%22lastName%22%3A%22Messonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Vilmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joevin%22%2C%22lastName%22%3A%22Sourdon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Sickle%20cell%20disease%20%28SCD%29%20is%20an%20hemoglobinopathy%20resulting%20in%20the%20production%20of%20an%20abnormal%20Hb%20%28HbS%29%20which%20can%20polymerize%20in%20deoxygenated%20conditions%2C%20leading%20to%20the%20sickling%20of%20red%20blood%20cells%20%28RBC%29.%20These%20alterations%20can%20decrease%20the%20oxygen-carrying%20capacity%20leading%20to%20impaired%20function%20and%20energetics%20of%20skeletal%20muscle.%20Any%20strategy%20which%20could%20reverse%20the%20corresponding%20defects%20could%20be%20of%20interest.%20In%20SCD%2C%20endurance%20training%20is%20known%20to%20improve%20multiples%20muscle%20properties%20which%20restores%20patient%26%23039%3Bs%20exercise%20capacity%20but%20present%20reduced%20effects%20in%20anemic%20patients.%20Hydroxyurea%20%28HU%29%20can%20increase%20fetal%20hemoglobin%20production%20which%20can%20reduce%20anemia%20in%20patients.%20The%20present%20study%20was%20conducted%20to%20determine%20whether%20HU%20can%20improve%20the%20effects%20of%20endurance%20training%20to%20improve%20muscle%20function%20and%20energetics.%20Twenty%20SCD%20Townes%20mice%20have%20been%20trained%20for%208%5Cu00a0weeks%20with%20%28n%5Cu00a0%3D%5Cu00a011%29%20or%20without%20%28n%5Cu00a0%3D%5Cu00a09%29%20HU.%20SCD%20mice%20muscle%20function%20and%20energetics%20were%20analyzed%20during%20a%20standardized%20rest-exercise-recovery%20protocol%2C%20using%20Phosphorus-31%20Magnetic%20resonance%20spectroscopy%20%2831P-MRS%29%20and%20transcutaneous%20stimulation.%20The%20combination%20of%20training%20and%20HU%20specifically%20decreased%20fatigue%20index%20and%20PCr%20consumption%20while%20muscle%20oxidative%20capacity%20was%20improved.%20These%20results%20illustrate%20the%20potential%20synergistic%20effects%20of%20endurance%20training%20and%20HU%20on%20muscle%20function%20and%20energetics%20in%20sickle%20cell%20disease.%22%2C%22date%22%3A%222024-03-29%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bcmd.2024.102853%22%2C%22ISSN%22%3A%221096-0961%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22DN66MWNE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jouvenot%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJouvenot%2C%20G.%2C%20Courbon%2C%20G.%2C%20Lefort%2C%20M.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%2C%20Edan%2C%20G.%2C%20de%20Seze%2C%20J.%2C%20Kremer%2C%20L.%2C%20Bigaut%2C%20K.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al-Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Cabre%2C%20P.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Moulin%2C%20S.%2C%20Ben-Nasr%2C%20H.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Neau%2C%20J.-P.%2C%20Pottier%2C%20C.%2C%20Nifle%2C%20C.%2C%20Collongues%2C%20N.%2C%20Kerbrat%2C%20A.%20and%20OFSEP%20Investigators%20%282024%29%20%26%23x201C%3BHigh-Efficacy%20Therapy%20Discontinuation%20vs%20Continuation%20in%20Patients%2050%20Years%20and%20Older%20With%20Nonactive%20MS%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%20neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20e240395.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2024.0395%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2024.0395%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-Efficacy%20Therapy%20Discontinuation%20vs%20Continuation%20in%20Patients%2050%20Years%20and%20Older%20With%20Nonactive%20MS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Jouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilhem%22%2C%22lastName%22%3A%22Courbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haifa%22%2C%22lastName%22%3A%22Ben-Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20A%20recent%20randomized%20clinical%20trial%20concluded%20that%20discontinuing%20medium-efficacy%20therapy%20might%20be%20a%20reasonable%20option%20for%20older%20patients%20with%20nonactive%20multiple%20sclerosis%20%28MS%29%2C%20but%20there%20is%20a%20lack%20of%20data%20on%20discontinuing%20high-efficacy%20therapy%20%28HET%29.%20In%20younger%20patients%2C%20the%20discontinuation%20of%20natalizumab%20and%20fingolimod%20is%20associated%20with%20a%20risk%20of%20rebound%20of%20disease%20activity.%5CnOBJECTIVE%3A%20To%20determine%20whether%20discontinuing%20HET%20in%20patients%2050%20years%20and%20older%20with%20nonactive%20MS%20is%20associated%20with%20an%20increased%20risk%20of%20relapse%20compared%20with%20continuing%20HET.%5CnDESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20This%20observational%20cohort%20study%20used%20data%20from%2038%20referral%20centers%20from%20the%20French%20MS%20registry%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%5BOFSEP%5D%20database%29.%20Among%2084704%20patients%20in%20the%20database%2C%20data%20were%20extracted%20for%201857%20patients%2050%20years%20and%20older%20with%20relapsing-remitting%20MS%20treated%20by%20HET%20and%20with%20no%20relapse%20or%20magnetic%20resonance%20imaging%20activity%20for%20at%20least%202%20years.%20After%20verification%20of%20the%20medical%20records%2C%201620%20patients%20were%20classified%20as%20having%20discontinued%20HET%20or%20having%20remained%20taking%20treatment%20and%20were%20matched%201%3A1%20using%20a%20dynamic%20propensity%20score%20%28including%20age%2C%20sex%2C%20disease%20phenotype%2C%20disability%2C%20treatment%20of%20interest%2C%20and%20time%20since%20last%20inflammatory%20activity%29.%20Patients%20were%20included%20from%20February%202008%20to%20November%202021%2C%20with%20a%20mean%20%28SD%29%20follow-up%20of%205.1%20%282.9%29%20years.%20Data%20were%20extracted%20in%20June%202022.%5CnEXPOSURES%3A%20Natalizumab%2C%20fingolimod%2C%20rituximab%2C%20and%20ocrelizumab.%5CnMAIN%20OUTCOMES%20AND%20MEASURES%3A%20Time%20to%20first%20relapse.%5CnRESULTS%3A%20Of%201620%20included%20patients%2C%201175%20%2872.5%25%29%20were%20female%2C%20and%20the%20mean%20%28SD%29%20age%20was%2054.7%20%284.8%29%20years.%20Among%20the%201452%20in%20the%20HET%20continuation%20group%20and%20168%20in%20the%20HET%20discontinuation%20group%2C%20154%20patients%20in%20each%20group%20were%20matched%20using%20propensity%20scores%20%28mean%20%5BSD%5D%20age%2C%2057.7%20%5B5.5%5D%20years%3B%20mean%20%5BSD%5D%20delay%20since%20the%20last%20inflammatory%20activity%2C%205.6%20%5B3.8%5D%20years%3B%20mean%20%5BSD%5D%20follow-up%20duration%20after%20propensity%20score%20matching%2C%202.5%20%5B2.1%5D%20years%29.%20Time%20to%20first%20relapse%20was%20significantly%20reduced%20in%20the%20HET%20discontinuation%20group%20compared%20with%20the%20HET%20continuation%20group%20%28hazard%20ratio%2C%204.1%3B%2095%25%20CI%2C%202.0-8.5%3B%20P%5Cu2009%26lt%3B%5Cu2009.001%29%20but%20differed%20between%20HETs%2C%20with%20a%20hazard%20ratio%20of%207.2%20%2895%25%20CI%2C%202.1-24.5%3B%20P%5Cu2009%3D%5Cu2009.001%29%20for%20natalizumab%2C%204.5%20%2895%25%20CI%2C%201.3-15.5%3B%20P%5Cu2009%3D%5Cu2009.02%29%20for%20fingolimod%2C%20and%201.1%20%2895%25%20CI%2C%200.3-4.8%3B%20P%5Cu2009%3D%5Cu2009.85%29%20for%20anti-CD20%20therapy.%5CnCONCLUSION%20AND%20RELEVANCE%3A%20As%20in%20younger%20patients%2C%20in%20patients%2050%20years%20and%20older%20with%20nonactive%20MS%2C%20the%20risk%20of%20relapse%20increased%20significantly%20after%20stopping%20HETs%20that%20impact%20immune%20cell%20trafficking%20%28natalizumab%20and%20fingolimod%29.%20There%20was%20no%20significant%20increase%20in%20risk%20after%20stopping%20HETs%20that%20deplete%20B-cells%20%28anti-CD20%20therapy%29.%20This%20result%20may%20inform%20decisions%20about%20stopping%20HETs%20in%20clinical%20practice.%22%2C%22date%22%3A%222024-03-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamaneurol.2024.0395%22%2C%22ISSN%22%3A%222168-6157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22KKHFI6XV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22White%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWhite%2C%20M.S.%2C%20Ogier%2C%20A.C.%2C%20Chenevert%2C%20T.L.%2C%20Zucker%2C%20E.%2C%20Stoneback%2C%20L.%2C%20Michel%2C%20C.P.%2C%20Palmieri-Smith%2C%20R.M.%20and%20Lepley%2C%20L.K.%20%282024%29%20%26%23x201C%3BBeyond%20weakness%3A%20Exploring%20intramuscular%20fat%20and%20quadriceps%20atrophy%20in%20ACLR%20recovery%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Orthopaedic%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%2042%2811%29%2C%20pp.%202485%26%23x2013%3B2494.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjor.25910%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjor.25910%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Beyond%20weakness%3A%20Exploring%20intramuscular%20fat%20and%20quadriceps%20atrophy%20in%20ACLR%20recovery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22McKenzie%20S.%22%2C%22lastName%22%3A%22White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%20C.%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20L.%22%2C%22lastName%22%3A%22Chenevert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zucker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luke%22%2C%22lastName%22%3A%22Stoneback%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riann%20M.%22%2C%22lastName%22%3A%22Palmieri-Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lindsey%20K.%22%2C%22lastName%22%3A%22Lepley%22%7D%5D%2C%22abstractNote%22%3A%22Muscle%20weakness%20following%20anterior%20cruciate%20ligament%20reconstruction%20%28ACLR%29%20increases%20the%20risk%20of%20posttraumatic%20osteoarthritis%20%28OA%29.%20However%2C%20focusing%20solely%20on%20muscle%20weakness%20overlooks%20other%20aspects%20like%20muscle%20composition%2C%20which%20could%20hinder%20strength%20recovery.%20Intramuscular%20fat%20is%20a%20non-contractile%20element%20linked%20to%20joint%20degeneration%20in%20idiopathic%20OA%2C%20but%20its%20role%20post-ACLR%20has%20not%20been%20thoroughly%20investigated.%20To%20bridge%20this%20gap%2C%20we%20aimed%20to%20characterize%20quadriceps%20volume%20and%20intramuscular%20fat%20in%20participants%20with%20ACLR%20%28male%5C%2Ffemale%20%3D%2015%5C%2F9%2C%20age%20%3D%2022.8%20%5Cu00b1%203.6%20years%2C%20body%20mass%20index%20%5BBMI%5D%20%3D%2023.2%20%5Cu00b1%201.9%2C%20time%20since%20surgery%20%3D%203.3%20%5Cu00b1%200.9%20years%29%20and%20in%20controls%20%28male%5C%2Ffemale%20%3D%2014%5C%2F10%2C%20age%20%3D%2022.0%20%5Cu00b1%203.1%20years%2C%20BMI%20%3D%2023.3%20%5Cu00b1%202.6%29%20while%20also%20exploring%20the%20associations%20between%20intramuscular%20fat%20and%20muscle%20volume%20with%20isometric%20strength.%20Linear%20mixed%20effects%20models%20assessed%20%28I%29%20muscle%20volume%2C%20%28II%29%20intramuscular%20fat%2C%20and%20%28III%29%20strength%20between%20limbs%20%28ACLR%20vs.%20contralateral%20vs.%20control%29.%20Regression%20analyses%20were%20run%20to%20determine%20if%20intramuscular%20fat%20or%20volume%20were%20associated%20with%20quadriceps%20strength.%20The%20ACLR%20limb%20was%208%25%5Cu221211%25%20smaller%20than%20the%20contralateral%20limb%20%28p%20%26lt%3B%200.05%29.%20No%20between-limb%20differences%20in%20intramuscular%20fat%20were%20observed%20%28p%20%3D%200.091%5Cu22120.997%29.%20Muscle%20volume%20but%20not%20intramuscular%20fat%20was%20associated%20with%20strength%20in%20the%20ACLR%20and%20control%20limbs%20%28p%20%26lt%3B%200.001%5Cu22120.002%29.%20We%20demonstrate%20that%20intramuscular%20fat%20does%20not%20appear%20to%20be%20an%20additional%20source%20of%20quadriceps%20dysfunction%20following%20ACLR%20and%20that%20muscle%20size%20only%20explains%20some%20of%20the%20variance%20in%20muscle%20strength.%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fjor.25910%22%2C%22ISSN%22%3A%221554-527X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fjor.25910%22%2C%22collections%22%3A%5B%2248SZ2I24%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A23Z%22%7D%7D%2C%7B%22key%22%3A%227FHVK5PB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guenoun%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuenoun%2C%20D.%2C%20Wirth%2C%20T.%2C%20Roche%2C%20D.%2C%20Michel%2C%20C.P.%2C%20Daud%26%23xE9%3B%2C%20P.%2C%20Ogier%2C%20A.C.%2C%20Chagnaud%2C%20C.%2C%20Mattei%2C%20J.P.%2C%20Pini%2C%20L.%2C%20Guye%2C%20M.%2C%20Ollivier%2C%20M.%2C%20Bendahan%2C%20D.%20and%20Guis%2C%20S.%20%282023%29%20%26%23x201C%3BUltra-high%20field%20magnetic%20resonance%20imaging%20of%20the%20quadriceps%20tendon%20enthesis%20in%20healthy%20subjects%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BSurgical%20and%20Radiologic%20Anatomy%26lt%3B%5C%2Fi%26gt%3B%2C%2045%288%29%2C%20pp.%201049%26%23x2013%3B1054.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ultra-high%20field%20magnetic%20resonance%20imaging%20of%20the%20quadriceps%20tendon%20enthesis%20in%20healthy%20subjects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daphne%22%2C%22lastName%22%3A%22Guenoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theo%22%2C%22lastName%22%3A%22Wirth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Roche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Daud%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%20C.%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Pini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Ollivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22Although%20enthesitis%20is%20a%20hallmark%20of%20several%20rheumatologic%20conditions%2C%20current%20imaging%20methods%20are%20still%20unable%20to%20characterize%20entheses%20changes%20because%20of%20the%20corresponding%20short%20transverse%20relaxation%20times%20%28T2%29.%20A%20growing%20number%20of%20MR%20studies%20have%20used%20Ultra-High%20Field%20%28UHF%29%20MRI%20in%20order%20to%20assess%20low-T2%20tissues%20e.g.%2C%20tendon%20but%20never%20in%20humans.%20The%20purpose%20of%20the%20present%20study%20was%20to%20assess%20in%20vivo%20the%20enthesis%20of%20the%20quadriceps%20tendon%20in%20healthy%20subjects%20using%20UHF%20MRI.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00276-023-03175-y%22%2C%22ISSN%22%3A%221279-8517%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%226BEMAGEW%22%2C%2248SZ2I24%22%2C%22ZP8JD3DQ%22%2C%22ACGLJ26R%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-12-05T16%3A12%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22PTRQE4IA%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brocard%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrocard%2C%20G.%2C%20Casey%2C%20R.%2C%20Dufay%2C%20N.%2C%20Marignier%2C%20R.%2C%20Michel%2C%20L.%2C%20Hisbergues%2C%20M.%2C%20Ayrignac%2C%20X.%2C%20Lehmann%2C%20S.%2C%20Thouvenot%2C%20E.%2C%20Gallot%2C%20G.%2C%20Collongues%2C%20N.%2C%20Herpe%2C%20Y.-E.%2C%20Lebrun-Frenay%2C%20C.%2C%20Cotton%2C%20F.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Guillemin%2C%20F.%2C%20Moreau%2C%20T.%2C%20Pelletier%2C%20J.%2C%20Stankoff%2C%20B.%2C%20Vukusic%2C%20S.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.%20and%20OFSEP%20investigators%20and%20biobanks%20%282023%29%20%26%23x201C%3BThe%20biological%20sample%20collection%20of%20the%20OFSEP%20French%20MS%20registry%3A%20An%20essential%20tool%20dedicated%20to%20researchers%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20and%20Related%20Disorders%26lt%3B%5C%2Fi%26gt%3B%2C%2077%2C%20p.%20104872.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.msard.2023.104872%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.msard.2023.104872%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20biological%20sample%20collection%20of%20the%20OFSEP%20French%20MS%20registry%3A%20An%20essential%20tool%20dedicated%20to%20researchers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Brocard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Dufay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Hisbergues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geraldine%22%2C%22lastName%22%3A%22Gallot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves-Edouard%22%2C%22lastName%22%3A%22Herpe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Guillemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%20and%20biobanks%22%7D%5D%2C%22abstractNote%22%3A%22Today%26%23039%3Bs%20medicine%20strives%20to%20be%20personalized%2C%20preventive%2C%20predictive%20and%20participatory.%20This%20implies%20to%20have%20access%20to%20multimodal%20data%20to%20better%20characterize%20patients%20groups%20and%20to%20combine%20clinical%20and%20imaging%20data%20with%20high-quality%20biological%20samples.%20Collecting%20such%20data%20is%20one%20of%20the%20objectives%20of%20the%20Observatoire%20fran%5Cu00e7ais%20de%20la%20scl%5Cu00e9rose%20en%20plaques%20%28OFSEP%29%2C%20the%20French%20MS%20registry.%20On%20December%202022%2C%20the%20OFSEP%20biocollection%20includes%204%2C888%20patients%20with%20scientific%20characteristics%20and%20about%2090%2C000%20samples.%20Thanks%20to%20its%20richness%2C%20this%20biocollection%20open%20for%20the%20scientific%20community%2C%20contributes%20to%20address%20unmet%20needs%20in%20MS%20through%20identification%20of%20multiomics%20determinants%20of%20MS%20activity%2C%20progression%20and%20secondary%20effects.%22%2C%22date%22%3A%222023-07-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.msard.2023.104872%22%2C%22ISSN%22%3A%222211-0356%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22UP99ABS7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sabath%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSabath%26%23xE9%3B%2C%20C.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Leray%2C%20E.%2C%20Mathey%2C%20G.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Ciron%2C%20J.%2C%20Wiertlewski%2C%20S.%2C%20Ruet%2C%20A.%2C%20Pelletier%2C%20J.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Michel%2C%20L.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moisset%2C%20X.%2C%20Thouvenot%2C%20E.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Bakchine%2C%20S.%2C%20Stankoff%2C%20B.%2C%20Al%20Khedr%2C%20A.%2C%20Cabre%2C%20P.%2C%20Maillart%2C%20E.%2C%20Berger%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Hankiewicz%2C%20K.%2C%20Moreau%2C%20T.%2C%20Gout%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Labauge%2C%20P.%2C%20Montcuquet%2C%20A.%2C%20Defer%2C%20G.%2C%20Maurousset%2C%20A.%2C%20Maubeuge%2C%20N.%2C%20Dimitri%20Boulos%2C%20D.%2C%20Ben%20Nasr%2C%20H.%2C%20Nifle%2C%20C.%2C%20Casez%2C%20O.%2C%20Laplaud%2C%20D.-A.%20and%20Foucher%2C%20Y.%20%282023%29%20%26%23x201C%3BImproving%20the%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy%20in%20multiple%20sclerosis%3A%20A%20dynamic%20scoring%20system%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2029%282%29%2C%20pp.%20236%26%23x2013%3B247.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improving%20the%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy%20in%20multiple%20sclerosis%3A%20A%20dynamic%20scoring%20system%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Sabath%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Bakchine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Maubeuge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalia%22%2C%22lastName%22%3A%22Dimitri%20Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ha%5Cu00effa%22%2C%22lastName%22%3A%22Ben%20Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohann%22%2C%22lastName%22%3A%22Foucher%22%7D%5D%2C%22abstractNote%22%3A%22Background%3AIn%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%2C%20early%20identification%20of%20suboptimal%20responders%20can%20prevent%20disability%20progression.Objective%3AWe%20aimed%20to%20develop%20and%20validate%20a%20dynamic%20score%20to%20guide%20the%20early%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy.Methods%3AUsing%20time-dependent%20propensity%20scores%20%28PS%29%20from%20a%20French%20cohort%20of%2012%2C823%20patients%20with%20RRMS%2C%20we%20constructed%20one%20training%20and%20two%20validation%20PS-matched%20cohorts%20to%20compare%20the%20switched%20patients%20to%20second-line%20treatment%20and%20the%20maintained%20patients.%20We%20used%20a%20frailty%20Cox%20model%20for%20predicting%20individual%20hazard%20ratios%20%28iHRs%29.Results%3AFrom%20the%20validation%20PS-matched%20cohort%20of%20348%20independent%20patients%20with%20iHR%20%3F%200.69%2C%20we%20reported%20the%205-year%20relapse-free%20survival%20at%200.14%20%2895%25%20confidence%20interval%20%28CI%29%200.09%3F0.22%29%20for%20the%20waiting%20group%20and%200.40%20%2895%25%20CI%200.32%3F0.51%29%20for%20the%20switched%20group.%20From%20the%20validation%20PS-matched%20cohort%20of%20518%20independent%20patients%20with%20iHR%20%26gt%3B%200.69%2C%20these%20values%20were%200.37%20%2895%25%20CI%200.30%3F0.46%29%20and%200.44%20%2895%25%20CI%200.37%3F0.52%29%2C%20respectively.Conclusions%3ABy%20using%20the%20proposed%20dynamic%20score%2C%20we%20estimated%20that%20at%20least%20one-third%20of%20patients%20could%20benefit%20from%20an%20earlier%20switch%20to%20prevent%20relapse.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221139156%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22TAQA93I8%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Michel%20et%20al.%22%2C%22parsedDate%22%3A%222023-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMichel%2C%20C.P.%2C%20Bendahan%2C%20D.%2C%20Giannesini%2C%20B.%2C%20Vilmen%2C%20C.%2C%20Le%20Fur%2C%20Y.%20and%20Messonnier%2C%20L.A.%20%282023%29%20%26%23x201C%3BEffects%20of%20hydroxyurea%20on%20skeletal%20muscle%20energetics%20and%20force%20production%20in%20a%20sickle%20cell%20disease%20murine%20model%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Applied%20Physiology%26lt%3B%5C%2Fi%26gt%3B%2C%20134%282%29%2C%20pp.%20415%26%23x2013%3B425.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1152%5C%2Fjapplphysiol.00333.2022%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1152%5C%2Fjapplphysiol.00333.2022%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20hydroxyurea%20on%20skeletal%20muscle%20energetics%20and%20force%20production%20in%20a%20sickle%20cell%20disease%20murine%20model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Vilmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20A.%22%2C%22lastName%22%3A%22Messonnier%22%7D%5D%2C%22abstractNote%22%3A%22Download%20figureDownload%20PowerPoint%22%2C%22date%22%3A%222023-02%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1152%5C%2Fjapplphysiol.00333.2022%22%2C%22ISSN%22%3A%228750-7587%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.physiology.org%5C%2Fdoi%5C%2Fabs%5C%2F10.1152%5C%2Fjapplphysiol.00333.2022%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%227FK4UDH9%22%2C%22NW6SZQBR%22%2C%226DHTGFMA%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A40%3A15Z%22%7D%7D%2C%7B%22key%22%3A%229LHNIBIX%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vukusic%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVukusic%2C%20S.%2C%20Marignier%2C%20R.%2C%20Ciron%2C%20J.%2C%20Bourre%2C%20B.%2C%20Cohen%2C%20M.%2C%20Deschamps%2C%20R.%2C%20Guillaume%2C%20M.%2C%20Kremer%2C%20L.%2C%20Pique%2C%20J.%2C%20Carra-Dalliere%2C%20C.%2C%20Michel%2C%20L.%2C%20Leray%2C%20E.%2C%20Guennoc%2C%20A.-M.%2C%20Laplaud%2C%20D.%2C%20Androdias%2C%20G.%2C%20Bensa%2C%20C.%2C%20Bigaut%2C%20K.%2C%20Biotti%2C%20D.%2C%20Branger%2C%20P.%2C%20Casez%2C%20O.%2C%20Daval%2C%20E.%2C%20Donze%2C%20C.%2C%20Dubessy%2C%20A.-L.%2C%20Dulau%2C%20C.%2C%20Durand-Dubief%2C%20F.%2C%20Hebant%2C%20B.%2C%20Kwiatkowski%2C%20A.%2C%20Lannoy%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Manchon%2C%20E.%2C%20Mathey%2C%20G.%2C%20Moisset%2C%20X.%2C%20Montcuquet%2C%20A.%2C%20Roux%2C%20T.%2C%20Maillart%2C%20E.%20and%20Lebrun-Frenay%2C%20C.%20%282023%29%20%26%23x201C%3BPregnancy%20and%20neuromyelitis%20optica%20spectrum%20disorders%3A%202022%20recommendations%20from%20the%20French%20Multiple%20Sclerosis%20Society%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2029%281%29%2C%20pp.%2037%26%23x2013%3B51.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221130934%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221130934%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pregnancy%20and%20neuromyelitis%20optica%20spectrum%20disorders%3A%202022%20recommendations%20from%20the%20French%20Multiple%20Sclerosis%20Society%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalliere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Guennoc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Daval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Donze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dulau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Hebant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Lannoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%5D%2C%22abstractNote%22%3A%22Background%3AIn%202020%2C%20the%20French%20Multiple%20Sclerosis%20%28MS%29%20Society%20%28SFSEP%29%20decided%20to%20develop%20a%20national%20evidence-based%20consensus%20on%20pregnancy%20in%20MS.%20As%20neuromyelitis%20optica%20spectrum%20disorders%20%28NMOSD%29%20shares%20a%20series%20of%20commonalities%20with%20MS%2C%20but%20also%20some%20significant%20differences%2C%20specific%20recommendations%20had%20to%20be%20developed.Objectives%3ATo%20establish%20recommendations%20on%20pregnancy%20in%20women%20with%20NMOSD.Methods%3AThe%20French%20Group%20for%20Recommendations%20in%20Multiple%20Sclerosis%20%28France4MS%29%20reviewed%20PubMed%20and%20universities%20databases%20%28January%201975%20through%20June%202021%29.%20The%20RAND%5C%2FUCLA%20appropriateness%20method%2C%20which%20was%20developed%20to%20synthesise%20the%20scientific%20literature%20and%20expert%20opinions%20on%20health%20care%20topics%2C%20was%20used%20to%20reach%20a%20formal%20agreement.%20Fifty-six%20MS%20experts%20worked%20on%20the%20full-text%20review%20and%20initial%20wording%20of%20recommendations.%20A%20sub-group%20of%20nine%20NMOSD%20experts%20was%20dedicated%20to%20analysing%20available%20data%20on%20NMOSD.%20A%20group%20of%2062%20multidisciplinary%20healthcare%20specialists%20validated%20the%20final%20proposal%20of%20summarised%20evidence.Results%3AA%20strong%20agreement%20was%20reached%20for%20all%2066%20proposed%20recommendations.%20They%20cover%20diverse%20topics%2C%20such%20as%20pregnancy%20planning%2C%20follow-up%20during%20pregnancy%20and%20postpartum%2C%20delivery%20routes%2C%20loco-regional%20analgesia%20or%20anaesthesia%2C%20prevention%20of%20postpartum%20relapses%2C%20breastfeeding%2C%20vaccinations%2C%20reproductive%20assistance%2C%20management%20of%20relapses%2C%20and%20disease-modifying%20treatments.Conclusion%3APhysicians%20and%20patients%20should%20be%20aware%20of%20the%20new%20and%20specific%20evidence-based%20recommendations%20of%20the%20French%20MS%20Society%20for%20pregnancy%20in%20women%20with%20NMOSD.%20They%20should%20help%20harmonise%20counselling%20and%20treatment%20practise%2C%20allowing%20for%20better%20individualised%20choices.%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221130934%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221130934%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A54%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22L2PDYDUD%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vukusic%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVukusic%2C%20S.%2C%20Carra-Dalliere%2C%20C.%2C%20Ciron%2C%20J.%2C%20Maillart%2C%20E.%2C%20Michel%2C%20L.%2C%20Leray%2C%20E.%2C%20Guennoc%2C%20A.-M.%2C%20Bourre%2C%20B.%2C%20Laplaud%2C%20D.%2C%20Androdias%2C%20G.%2C%20Bensa%2C%20C.%2C%20Bigaut%2C%20K.%2C%20Biotti%2C%20D.%2C%20Branger%2C%20P.%2C%20Casez%2C%20O.%2C%20Cohen%2C%20M.%2C%20Daval%2C%20E.%2C%20Deschamps%2C%20R.%2C%20Donze%2C%20C.%2C%20Dubessy%2C%20A.-L.%2C%20Dulau%2C%20C.%2C%20Durand-Dubief%2C%20F.%2C%20Guillaume%2C%20M.%2C%20Hebant%2C%20B.%2C%20Kremer%2C%20L.%2C%20Kwiatkowski%2C%20A.%2C%20Lannoy%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Manchon%2C%20E.%2C%20Mathey%2C%20G.%2C%20Moisset%2C%20X.%2C%20Montcuquet%2C%20A.%2C%20Pique%2C%20J.%2C%20Roux%2C%20T.%2C%20Marignier%2C%20R.%20and%20Lebrun-Frenay%3B%2C%20C.%20%282023%29%20%26%23x201C%3BPregnancy%20and%20multiple%20sclerosis%3A%202022%20recommendations%20from%20the%20French%20multiple%20sclerosis%20society%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2029%281%29%2C%20pp.%2011%26%23x2013%3B36.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221129472%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221129472%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pregnancy%20and%20multiple%20sclerosis%3A%202022%20recommendations%20from%20the%20French%20multiple%20sclerosis%20society%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Carra-Dalliere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22Guennoc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Daval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Donze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dulau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Hebant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Lannoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%3B%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3AThe%20objective%20of%20this%20study%20was%20to%20develop%20evidence-based%20recommendations%20on%20pregnancy%20management%20for%20persons%20with%20multiple%20sclerosis%20%28MS%29.Background%3AMS%20typically%20affects%20young%20women%20in%20their%20childbearing%20years.%20Increasing%20evidence%20is%20available%20to%20inform%20questions%20raised%20by%20MS%20patients%20and%20health%20professionals%20about%20pregnancy%20issues.Methods%3AThe%20French%20Group%20for%20Recommendations%20in%20Multiple%20Sclerosis%20%28France4MS%29%20reviewed%20PubMed%20and%20university%20databases%20%28January%201975%20through%20June%202021%29.%20The%20RAND%5C%2FUCLA%20appropriateness%20method%20was%20developed%20to%20synthesise%20the%20scientific%20literature%20and%20expert%20opinions%20on%20healthcare%20topics%3B%20it%20was%20used%20to%20reach%20a%20formal%20agreement.%20Fifty-six%20MS%20experts%20worked%20on%20the%20full-text%20review%20and%20initial%20wording%20of%20recommendations.%20A%20group%20of%2062%20multidisciplinary%20healthcare%20specialists%20validated%20the%20final%20proposal%20of%20summarised%20evidence.Results%3AA%20strong%20agreement%20was%20reached%20for%20all%20104%20proposed%20recommendations.%20They%20cover%20diverse%20topics%2C%20such%20as%20pregnancy%20planning%2C%20follow-up%20during%20pregnancy%20and%20postpartum%2C%20delivery%20routes%2C%20locoregional%20analgesia%20or%20anaesthesia%2C%20prevention%20of%20postpartum%20relapses%2C%20breastfeeding%2C%20vaccinations%2C%20reproductive%20assistance%2C%20management%20of%20relapses%20and%20disease-modifying%20treatments.Conclusion%3AThe%202022%20recommendations%20of%20the%20French%20MS%20society%20should%20be%20helpful%20to%20harmonise%20counselling%20and%20treatment%20practice%20for%20pregnancy%20in%20persons%20with%20MS%2C%20allowing%20for%20better%20and%20individualised%20choices.%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221129472%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221129472%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A54%3A40Z%22%7D%7D%2C%7B%22key%22%3A%2237VZFDGX%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durelle%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDurelle%2C%20C.%2C%20Delmont%2C%20E.%2C%20Michel%2C%20C.%2C%20Trabelsi%2C%20A.%2C%20Hostin%2C%20M.-A.%2C%20Ogier%2C%20A.%2C%20Bendahan%2C%20D.%20and%20Attarian%2C%20S.%20%282023%29%20%26%23x201C%3BQuantification%20of%20muscle%20involvement%20in%20familial%20amyloid%20polyneuropathy%20using%20MRI%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2030%2810%29%2C%20pp.%203286%26%23x2013%3B3295.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.15970%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.15970%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quantification%20of%20muscle%20involvement%20in%20familial%20amyloid%20polyneuropathy%20using%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Durelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amira%22%2C%22lastName%22%3A%22Trabelsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Adrien%22%2C%22lastName%22%3A%22Hostin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20purpose%20Transthyretin%20familial%20amyloid%20polyneuropathy%20%28TTR-FAP%29%20is%20a%20rare%20genetic%20disease%20with%20autosomal-dominant%20inheritance.%20In%20this%20study%2C%20we%20aimed%20to%20quantify%20fatty%20infiltration%20%28fat%20fraction%20%5BFF%5D%29%20and%20magnetization%20transfer%20ratio%20%28MTR%29%20in%20individual%20muscles%20of%20patients%20with%20symptomatic%20and%20asymptomatic%20TTR-FAP%20using%20magnetic%20resonance%20imaging.%20Secondarily%2C%20we%20aimed%20to%20assess%20correlations%20with%20clinical%20and%20electrophysiological%20variables.%20Methods%20A%20total%20of%2039%20patients%20with%20a%20confirmed%20mutation%20in%20the%20TTR%20gene%20%2825%20symptomatic%20and%2014%20asymptomatic%29%20and%2014%20healthy%20volunteers%20were%20included.%20A%20total%20of%2016%20muscles%20were%20manually%20delineated%20in%20the%20nondominant%20lower%20limb%20from%20T1-weighted%20anatomical%20images.%20The%20corresponding%20masks%20were%20propagated%20on%20the%20MTR%20and%20FF%20maps.%20Detailed%20neurological%20and%20electrophysiological%20examinations%20were%20conducted%20in%20each%20group.%20Results%20The%20MTR%20was%20decreased%20%2842.6%20AU%3B%20p%20%3D%200.001%29%20and%20FF%20was%20elevated%20%2814%25%3B%20p%20%3D%200.003%29%20in%20the%20lower%20limbs%20of%20the%20symptomatic%20group%2C%20with%20preferential%20posterior%20and%20lateral%20involvement.%20In%20the%20asymptomatic%20group%2C%20elevated%20FF%20was%20quantified%20in%20the%20gastrocnemius%20lateralis%20muscle%20%2811%25%3B%20p%20%3D%200.021%29.%20FF%20was%20significantly%20correlated%20with%20disease%20duration%20%28r%20%3D%200.49%2C%20p%20%3D%200.015%29%2C%20neuropathy%20impairment%20score%20for%20the%20lower%20limb%20%28r%20%3D%200.42%2C%20p%20%3D%200.041%29%2C%20Overall%20Neuropathy%20Limitations%20Scale%20score%20%28r%20%3D%200.49%2C%20p%20%3D%200.013%29%2C%20polyneuropathy%20disability%20score%20%28r%20%3D%200.57%2C%20p%20%3D%200.03%29%20and%20the%20sum%20of%20compound%20muscle%20action%20potential%20%28r%20%3D%200.52%2C%20p%20%3D%200.009%29.%20MTR%20was%20strongly%20correlated%20to%20FF%20%28r%20%3D%200.78%2C%20p%20%26lt%3B%200.0001%29%2C%20and%20a%20few%20muscles%20with%20an%20FF%20within%20the%20normal%20range%20had%20a%20reduced%20MTR.%20Conclusion%20These%20observations%20suggest%20that%20FF%20and%20MTR%20could%20be%20interesting%20biomarkers%20in%20TTR-FAP.%20In%20asymptomatic%20patients%2C%20FF%20in%20the%20gastrocnemius%20lateralis%20muscle%20could%20be%20a%20good%20indicator%20of%20the%20transition%20from%20an%20asymptomatic%20to%20a%20symptomatic%20form%20of%20the%20disease.%20MTR%20could%20be%20an%20early%20biomarker%20of%20muscle%20alterations.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.15970%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fene.15970%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%2248SZ2I24%22%5D%2C%22dateModified%22%3A%222025-09-11T07%3A32%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22QUUBG9E5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hostin%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHostin%2C%20M.-A.%2C%20Ogier%2C%20A.C.%2C%20Michel%2C%20C.P.%2C%20Le%20Fur%2C%20Y.%2C%20Guye%2C%20M.%2C%20Attarian%2C%20S.%2C%20Fortanier%2C%20E.%2C%20Bellemare%2C%20M.-E.%20and%20Bendahan%2C%20D.%20%282023%29%20%26%23x201C%3BThe%20Impact%20of%20Fatty%20Infiltration%20on%20MRI%20Segmentation%20of%20Lower%20Limb%20Muscles%20in%20Neuromuscular%20Diseases%3A%20A%20Comparative%20Study%20of%20Deep%20Learning%20Approaches%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Magnetic%20Resonance%20Imaging%26lt%3B%5C%2Fi%26gt%3B%2C%2058%286%29%2C%20pp.%201826%26%23x2013%3B1835.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmri.28708%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmri.28708%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20Fatty%20Infiltration%20on%20MRI%20Segmentation%20of%20Lower%20Limb%20Muscles%20in%20Neuromuscular%20Diseases%3A%20A%20Comparative%20Study%20of%20Deep%20Learning%20Approaches%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Adrien%22%2C%22lastName%22%3A%22Hostin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%20C.%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc-Emmanuel%22%2C%22lastName%22%3A%22Bellemare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Deep%20learning%20methods%20have%20been%20shown%20to%20be%20useful%20for%20segmentation%20of%20lower%20limb%20muscle%20MRIs%20of%20healthy%20subjects%20but%2C%20have%20not%20been%20sufficiently%20evaluated%20on%20neuromuscular%20disease%20%28NDM%29%20patients.%20Purpose%20Evaluate%20the%20influence%20of%20fat%20infiltration%20on%20convolutional%20neural%20network%20%28CNN%29%20segmentation%20of%20MRIs%20from%20NMD%20patients.%20Study%20Type%20Retrospective%20study.%20Subjects%20Data%20were%20collected%20from%20a%20hospital%20database%20of%2067%20patients%20with%20NMDs%20and%2014%20controls%20%28age%3A%2053%20%5Cu00b1%2017%20years%2C%20sex%3A%2048%20M%2C%2033%20F%29.%20Ten%20individual%20muscles%20were%20segmented%20from%20the%20thigh%20and%20six%20from%20the%20calf%20%2820%20slices%2C%20200%20cm%20section%29.%20Field%20Strength%5C%2FSequence%20A%201.5%20T.%20Sequences%3A%202D%20T1-weighted%20fast%20spin%20echo.%20Fat%20fraction%20%28FF%29%3A%20three-point%20Dixon%203D%20GRE%2C%20magnetization%20transfer%20ratio%20%28MTR%29%3A%203D%20MT-prepared%20GRE%2C%20T2%3A%202D%20multispin-echo%20sequence.%20Assessment%20U-Net%202D%2C%20U-Net%203D%2C%20TransUNet%2C%20and%20HRNet%20were%20trained%20to%20segment%20thigh%20and%20leg%20muscles%20%28101%5C%2F11%20and%2095%5C%2F11%20training%5C%2Fvalidation%20images%2C%2010-fold%20cross-validation%29.%20Automatic%20and%20manual%20segmentations%20were%20compared%20based%20on%20geometric%20criteria%20%28Dice%20coefficient%20%5BDSC%5D%2C%20outlier%20rate%2C%20absence%20rate%29%20and%20reliability%20of%20measured%20MRI%20quantities%20%28FF%2C%20MTR%2C%20T2%2C%20volume%29.%20Statistical%20Tests%20Bland%5Cu2013Altman%20plots%20were%20chosen%20to%20describe%20agreement%20between%20manual%20vs.%20automatic%20estimated%20FF%2C%20MTR%2C%20T2%20and%20volume.%20Comparisons%20were%20made%20between%20muscle%20populations%20with%20an%20FF%20greater%20than%2020%25%20%28G20%2B%29%20and%20lower%20than%2020%25%20%28G20%5Cu2212%29.%20Results%20The%20CNNs%20achieved%20equivalent%20results%2C%20yet%20only%20HRNet%20recognized%20every%20muscle%20in%20the%20database%2C%20with%20a%20DSC%20of%200.91%20%5Cu00b1%200.08%2C%20and%20measurement%20biases%20reaching%20%5Cu22120.32%25%20%5Cu00b1%200.92%25%20for%20FF%2C%200.19%20%5Cu00b1%200.77%20for%20MTR%2C%20%5Cu22120.55%20%5Cu00b1%201.95%20msec%20for%20T2%2C%20and%20%5Cu2212%200.38%20%5Cu00b1%203.67%20cm3%20for%20volume.%20The%20performances%20of%20HRNet%2C%20between%20G20%5Cu2212%20and%20G20%2B%20decreased%20significantly.%20Data%20Conclusion%20HRNet%20was%20the%20most%20appropriate%20network%2C%20as%20it%20did%20not%20omit%20any%20muscle.%20The%20accuracy%20obtained%20shows%20that%20CNNs%20could%20provide%20fully%20automated%20methods%20for%20studying%20NMDs.%20However%2C%20the%20accuracy%20of%20the%20methods%20may%20be%20degraded%20on%20the%20most%20infiltrated%20muscles%20%28%26gt%3B20%25%29.%20Evidence%20Level%204.%20Technical%20Efficacy%20Stage%201.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fjmri.28708%22%2C%22ISSN%22%3A%221522-2586%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fjmri.28708%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%22NW6SZQBR%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222025-04-23T10%3A05%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22N7JR5MZU%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demuth%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemuth%2C%20S.%2C%20Guillaume%2C%20M.%2C%20Bourre%2C%20B.%2C%20Ciron%2C%20J.%2C%20Zephir%2C%20H.%2C%20Sirejacob%2C%20Y.%2C%20Kerbrat%2C%20A.%2C%20Lebrun-Frenay%2C%20C.%2C%20Papeix%2C%20C.%2C%20Michel%2C%20L.%2C%20Laplaud%2C%20D.%2C%20Vukusic%2C%20S.%2C%20Maillart%2C%20E.%2C%20Cohen%2C%20M.%2C%20Audoin%2C%20B.%2C%20Marignier%2C%20R.%2C%20Collongues%2C%20N.%20and%20NOMADMUS%20Study%20Group%20%282022%29%20%26%23x201C%3BTreatment%20regimens%20for%20neuromyelitis%20optica%20spectrum%20disorder%20attacks%3A%20a%20retrospective%20cohort%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2019%281%29%2C%20p.%2062.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-022-02420-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12974-022-02420-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20regimens%20for%20neuromyelitis%20optica%20spectrum%20disorder%20attacks%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Demuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoann%22%2C%22lastName%22%3A%22Sirejacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22NOMADMUS%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%20attacks%20require%20an%20urgent%20probabilistic%20anti-inflammatory%20therapeutic%20strategy.%20As%20inadequately%20treated%20attacks%20result%20in%20disability%2C%20there%20is%20a%20need%20to%20identify%20the%20optimal%20attack-treatment%20regimen.%20Our%20study%20aimed%20to%20identify%20predictors%20of%20outcome%20after%20a%20first%20attack%20in%20patients%20with%20an%20NMOSD%20presentation%20and%20propose%20the%20best%20treatment%20strategy.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20on%20the%20French%20national%20NMOSD%20registry%20%28NOMADMUS%29%2C%20a%20nested%20cohort%20of%20the%20French%20multiple%20sclerosis%20observatory%20%28OFSEP%29%20recruiting%20patients%20with%20NMOSD%20presentations%20in%20France.%20We%20studied%20the%20first%20attack%20for%20any%20independent%20locations%20of%20clinical%20core%20characteristic%20of%20NMOSD%2C%20in%20treatment-na%5Cu00efve%20patients.%20The%20primary%20outcome%20was%20the%20evolution%20of%20the%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20at%206%5Cu00a0months%2C%20stratified%20in%20two%20ways%20to%20account%20for%20recovery%20%28return%20to%20baseline%20EDSS%20score%29%20and%20treatment%20response%20%28classified%20as%20%26quot%3Bgood%26quot%3B%20if%20the%20EDSS%20score%20decreased%20by%20%5Cu2265%5Cu20091%20point%20after%20a%20nadir%20EDSS%20score%5Cu2009%5Cu2264%5Cu20093%2C%20or%20by%20%5Cu2265%5Cu20092%20points%20after%20a%20nadir%20EDSS%20score%5Cu2009%26gt%3B%5Cu20093%29.%20We%20used%20ordinal%20logistic%20regression%20to%20infer%20statistical%20associations%20with%20the%20outcome.%5CnRESULTS%3A%20We%20included%20211%20attacks%20among%20183%20patients%20%28104%20with%20anti-AQP4%20antibodies%2C%2060%20with%20anti-MOG%20antibodies%2C%20and%2019%20double%20seronegative%29.%20Attack%20treatment%20regimens%20comprised%20corticosteroids%20%28n%5Cu2009%3D%5Cu2009196%29%2C%20plasma%20exchanges%20%28PE%3B%20n%5Cu2009%3D%5Cu200972%29%20and%20intravenous%20immunoglobulins%20%28n%5Cu2009%3D%5Cu20096%29.%20Complete%20recovery%20was%20reached%20in%2040%20attacks%20%2819%25%29%20at%206%5Cu00a0months.%20The%20treatment%20response%20was%20%26quot%3Bgood%26quot%3B%20in%20134%20attacks%20%2863.5%25%29.%20There%20was%20no%20improvement%20in%20EDSS%20score%20in%2050%20attacks%20%2823.7%25%29.%20MOG-antibody%20seropositivity%20and%20short%20delays%20to%20PE%20were%20significantly%20and%20independently%20associated%20with%20better%20recovery%20and%20treatment%20response.%5CnCONCLUSIONS%3A%20We%20identified%20two%20prognostic%20factors%3A%20serostatus%20%28with%20better%20outcomes%20among%20MOG-Ab-positive%20patients%29%20and%20the%20delay%20to%20PE.%20We%2C%20therefore%2C%20argue%20for%20a%20more%20aggressive%20anti-inflammatory%20management%20of%20the%20first%20attacks%20suggesting%20an%20NMOSD%20presentation%2C%20with%20the%20early%20combination%20of%20PE%20with%20corticosteroids.%22%2C%22date%22%3A%222022-03-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12974-022-02420-2%22%2C%22ISSN%22%3A%221742-2094%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A39%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22K7XR38KN%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trojani%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTrojani%2C%20M.-C.%2C%20Chorin%2C%20F.%2C%20Gerus%2C%20P.%2C%20Breuil%2C%20V.%2C%20Michel%2C%20C.%2C%20Guis%2C%20S.%2C%20Bendahan%2C%20D.%20and%20Roux%2C%20C.%20%282022%29%20%26%23x201C%3BConcentric%20or%20eccentric%20physical%20activity%20for%20patients%20with%20symptomatic%20osteoarthritis%20of%20the%20knee%3A%20a%20randomized%20prospective%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BTherapeutic%20Advances%20in%20Musculoskeletal%20Disease%26lt%3B%5C%2Fi%26gt%3B%2C%2014%2C%20p.%201759720X221102805.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1759720X221102805%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1759720X221102805%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Concentric%20or%20eccentric%20physical%20activity%20for%20patients%20with%20symptomatic%20osteoarthritis%20of%20the%20knee%3A%20a%20randomized%20prospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Charlotte%22%2C%22lastName%22%3A%22Trojani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Chorin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gerus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Breuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Roux%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Knee%20osteoarthritis-related%20pain%20limits%20physical%20function%20and%20leads%20to%20functional%20disability.%20Physical%20activity%20is%20one%20of%20the%20central%20recommendations%20for%20the%20management%20of%20knee%20osteoarthritis.%20Although%20concentric%20muscle%20activities%20are%20often%20preferred%20to%20eccentric%20ones%2C%20the%20corresponding%20rationale%20remains%20controversial.%5CnOBJECTIVE%3A%20To%20explore%20the%20effect%20of%20a%206-week%20exercise%20program%20on%20function%2C%20pain%2C%20and%20performance%20in%20patients%20with%20symptomatic%20knee%20osteoarthritis.%5CnMETHODS%3A%20Patients%20with%20symptomatic%20knee%20osteoarthritis%20were%20included%20in%20the%20prospective%20EX-ART%20project%20%28Walking%20performance%20in%20osteoARThritic%20subjects%3A%20effect%20of%20an%20ECCentric%20muscle%20strengthening%20program%29%20and%20randomized%20in%20a%206-week%20rehabilitation%20program%20including%20either%20eccentric%20or%20concentric%20activities.%20Metrics%20of%20interest%20chosen%20as%20end%20points%20measured%20before%20and%20after%20the%20rehabilitation%20were%20WOMAC%20score%2C%20pain%2C%20and%20muscular%20performance%20%28quadriceps%20power%20PMAX%20and%20contraction%20strength%20MMAX%29.%20MRI%20was%20also%20used%20to%20assess%20muscle%20volume%20and%20fat%20infiltration%20changes.%5CnRESULTS%3A%2030%20patients%20were%20included%20in%20each%20group%3B%20mean%20age%20was%2074%20%28%5Cu00b17.6%29%3B%2069%25%20were%20women.%20At%20week%206%2C%20both%20groups%20showed%20a%20significant%20improvement%20in%20the%20WOMAC%20without%20difference%20between%20the%20two%20groups%20%28p%5Cu2009%3D%5Cu20090.7%29.%20No%20difference%20between%20the%20two%20groups%20was%20identified%20for%20the%20pain%20reduction%20%28p%5Cu2009%3D%5Cu20090.7%29.%20A%20significant%20improvement%20in%20the%20change%20in%20PMAX%20and%20MMAX%20at%20high%20velocity%20%28p%5Cu2009%3D%5Cu20090.001%20and%20p%5Cu2009%3D%5Cu20090.002%29%20was%20observed%20in%20the%20eccentric%20group%20only.%20A%20vastus%20medialis%20hypertrophy%20was%20quantified%20in%20the%20eccentric%20group%20only%20%28p%5Cu2009%3D%5Cu20090.002%29%2C%20whereas%20fat%20infiltration%20in%20the%20quadriceps%20muscles%20was%20unchanged.%5CnCONCLUSION%3A%20Physical%20activity%2C%20whether%20eccentric%20or%20concentric%2C%20has%20a%20benefit%20on%20function%20and%20pain%20in%20patients%20with%20symptomatic%20knee%20osteoarthritis.%20A%20few%20differences%20have%20been%20identified%20between%20the%20two%20types%20of%20rehabilitation.%20More%20particularly%2C%20a%20gain%20in%20muscle%20performance%20and%20vastus%20medialis%20volume%20was%20found%20with%20eccentric%20rehabilitation%20only.%5CnREGISTRATION%3A%20www.ClinicalTrials.gov%2C%20registration%20number%20NCT03167502.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1759720X221102805%22%2C%22ISSN%22%3A%221759-720X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22ZWKZEZH3%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Michel%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMichel%2C%20C.P.%2C%20Messonnier%2C%20L.A.%2C%20Giannesini%2C%20B.%2C%20Chatel%2C%20B.%2C%20Vilmen%2C%20C.%2C%20Le%20Fur%2C%20Y.%20and%20Bendahan%2C%20D.%20%282022%29%20%26%23x201C%3BEffects%20of%20Hydroxyurea%20on%20Skeletal%20Muscle%20Energetics%20and%20Function%20in%20a%20Mildly%20Anemic%20Mouse%20Model%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Physiology%26lt%3B%5C%2Fi%26gt%3B%2C%2013%2C%20p.%20915640.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffphys.2022.915640%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffphys.2022.915640%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20Hydroxyurea%20on%20Skeletal%20Muscle%20Energetics%20and%20Function%20in%20a%20Mildly%20Anemic%20Mouse%20Model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20A.%22%2C%22lastName%22%3A%22Messonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Chatel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Vilmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Hydroxyurea%20%28HU%29%20is%20a%20ribonucleotide%20reductase%20inhibitor%20most%20commonly%20used%20as%20a%20therapeutic%20agent%20in%20sickle%20cell%20disease%20%28SCD%29%20with%20the%20aim%20of%20reducing%20the%20risk%20of%20vaso-occlusion%20and%20improving%20oxygen%20transport%20to%20tissues.%20Previous%20studies%20suggest%20that%20HU%20may%20be%20even%20beneficial%20in%20mild%20anemia.%20However%2C%20the%20corresponding%20effects%20on%20skeletal%20muscle%20energetics%20and%20function%20have%20never%20been%20reported%20in%20such%20a%20mild%20anemia%20model.%20Seventeen%20mildly%20anemic%20HbAA%20Townes%20mice%20were%20subjected%20to%20a%20standardized%20rest-stimulation%20%28transcutaneous%20stimulation%29-protocol%20while%20muscle%20energetics%20using%2031Phosphorus%20magnetic%20resonance%20spectroscopy%20and%20muscle%20force%20production%20were%20assessed%20and%20recorded.%20Eight%20mice%20were%20supplemented%20with%20hydroxyurea%20%28HU%29%20for%206%20weeks%20while%209%20were%20not%20%28CON%29.%20HU%20mice%20displayed%20a%20higher%20specific%20total%20force%20production%20compared%20to%20the%20CON%2C%20with%20501.35%20%5Cu00b1%2054.12%5Cu00a0N%5C%2Fmm3%20and%20437.43%20%5Cu00b1%2057.10%5Cu00a0N%5C%2Fmm3%20respectively%20%28%2B14.6%25%2C%20p%20%26lt%3B%200.05%29.%20Neither%20the%20total%20rate%20of%20energy%20consumption%20nor%20the%20oxidative%20metabolic%20rate%20were%20significantly%20different%20between%20groups.%20The%20present%20results%20illustrated%20a%20positive%20effect%20of%20a%20HU%20chronic%20supplementation%20on%20skeletal%20muscle%20function%20in%20mice%20with%20mild%20anemia.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffphys.2022.915640%22%2C%22ISSN%22%3A%221664-042X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%227FK4UDH9%22%2C%22NW6SZQBR%22%2C%226DHTGFMA%22%2C%22HIWENPPK%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A40%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22NZ592LC2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarlon-Bartoli%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSarlon-Bartoli%2C%20G.%2C%20Michel%2C%20Q.%2C%20Sarlon%2C%20E.%2C%20Carcopino-Tusoli%2C%20M.%2C%20Suchon%2C%20P.%2C%20Soler%2C%20R.%2C%20Bartoli%2C%20M.A.%2C%20Brunet%2C%20D.%2C%20Morange%2C%20P.%20and%20Charbonnier%2C%20A.%20%282021%29%20%26%23x201C%3BUltrasound%20arterial%20anomalies%20in%20patients%20exposed%20to%20nilotinib%20therapy%20for%20chronic%20myeloid%20leukemia%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20De%20Medecine%20Vasculaire%26lt%3B%5C%2Fi%26gt%3B%2C%2046%282%29%2C%20pp.%2066%26%23x2013%3B71.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jdmv.2021.02.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jdmv.2021.02.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ultrasound%20arterial%20anomalies%20in%20patients%20exposed%20to%20nilotinib%20therapy%20for%20chronic%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sarlon-Bartoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sarlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Carcopino-Tusoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Suchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Soler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Bartoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Morange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Charbonnier%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Patients%20exposed%20to%20nilotinib%20for%20chronic%20myeloid%20leukemia%20%28CML%29%20appear%20to%20be%20at%20risk%20of%20arterial%20complication.%20The%20prevalence%20and%20aspect%20of%20ultrasound%20asymptomatic%20arterial%20lesions%20are%20unknown.%5CnOBJECTIVE%3A%20To%20describe%20prevalence%20and%20characteristics%20of%20ultrasound%20arterial%20anomalies%20in%20patients%20treated%20with%20nilotinib%20for%20CML.%5CnMETHODS%3A%20Patients%20treated%20with%20nilotinib%20from%202006%20to%202015%20in%20the%20department%20of%20the%20Paoli-Calmettes%20Institute%2C%20Marseille%2C%20were%20included%20retrospectively.%20A%20vascular%20ultrasound%20screening%20was%20carried%20out%20from%202010.%20The%20arterial%20lesions%20at%20the%20first%20examination%20were%20described%3A%20plaque%20and%20its%20echogenicity%2C%20stenosis%20or%20occlusion.%20A%20vascular%20arterial%20anomaly%20%28VAA%29%20was%20defined%20by%20the%20presence%20of%20a%20clinical%20and%5C%2For%20ultrasound%20anomaly.%20Patients%20with%20or%20without%20VAA%20at%20initial%20vascular%20examination%20were%20compared%20using%20bivariate%20and%20multivariate%20analysis.%5CnRESULTS%3A%2074%20patients%20were%20included%20%2851.4%25%20men%2C%20mean%20age%2054.5%20years%29%3B%2025%20patients%20had%20ultrasound%20arterial%20anomalies%20%2833.8%25%29.%20Carotid%20bulb%20was%20the%20most%20involved%20territory%20%2844%25%29.%20Arterial%20anomalies%20were%3A%2088%25%20plaques%2C%2044%25%26gt%3B50%25%20stenosis%20and%2012%25%20occlusion.%2072.7%25%20plaques%20were%20echolucent%20or%20hypoechogenic.%20A%20VAA%20was%20present%20in%2025%20patients%20with%20initial%20vascular%20evaluation%20%2833.8%25%29.%20Patients%20with%20VAA%20at%20baseline%20were%20significantly%20older%20%2864.9%20vs%2049.3%2C%20P%26lt%3B0.001%29%2C%20older%20at%20nilotinib%20initiation%20%2860.8%20vs%2046.5%2C%20P%26lt%3B0.001%29%2C%20with%20more%20arterial%20hypertension%20%2840%25%20vs%2012.2%25%2C%20P%3D0.01%29%2C%20with%20more%20cardiovascular%20risk%20factors%20%28P%3D0.03%29.%20In%20patient%20with%20no%20cardiovascular%20risk%20factor%2012.5%25%20had%20VAA%20%28n%3D24%29.%5CnCONCLUSION%3A%20Nilotinib%20seems%20to%20be%20associated%20to%20arterial%20lesions%20of%20unstable%20lipid-like%20appearance.%20The%20most%20involved%20arterial%20territory%20was%20the%20carotid%20bulb%20and%20the%20most%20common%20lesion%20was%20echolucent%20or%20hypoechogenic%20plaque.%20VAA%20can%20occur%20in%20patients%20without%20cardiovascular%20risk%20factors.%20This%20result%20encourages%20us%20to%20systematically%20screen%20and%20follow%20all%20patients%20exposed%20to%20nilotinib%20even%20those%20without%20cardiovascular%20risk%20factors.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jdmv.2021.02.002%22%2C%22ISSN%22%3A%222542-4513%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ADCRQM9R%22%2C%226J6Q3BTE%22%2C%22TXRC8BWU%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A39%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22IK9SV2R9%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chatel%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChatel%2C%20B.%2C%20Bernit%2C%20E.%2C%20Vilmen%2C%20C.%2C%20Michel%2C%20C.%2C%20Bendahan%2C%20D.%20and%20Messonnier%2C%20L.A.%20%282021%29%20%26%23x201C%3BIn%20vivo%20muscle%20function%20and%20energetics%20in%20women%20with%20sickle%20cell%20anemia%20or%20trait%3A%20a%2031P-magnetic%20resonance%20spectroscopy%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Applied%20Physiology%20%28Bethesda%2C%20Md.%3A%201985%29%26lt%3B%5C%2Fi%26gt%3B%2C%20130%283%29%2C%20pp.%20737%26%23x2013%3B745.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1152%5C%2Fjapplphysiol.00790.2020%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1152%5C%2Fjapplphysiol.00790.2020%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20muscle%20function%20and%20energetics%20in%20women%20with%20sickle%20cell%20anemia%20or%20trait%3A%20a%2031P-magnetic%20resonance%20spectroscopy%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Chatel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bernit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Vilmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20A.%22%2C%22lastName%22%3A%22Messonnier%22%7D%5D%2C%22abstractNote%22%3A%22Sickle%20cell%20anemia%20%28SCA%29%20is%20a%20genetic%20hemoglobinopathy%20associated%20with%20an%20impaired%20oxygen%20delivery%20to%20skeletal%20muscle%20that%20could%20alter%20ATP%20production%20processes%20and%20increase%20intramuscular%20acidosis.%20These%20alterations%20have%20been%20already%20reported%20in%20the%20Townes%20mouse%20model%20of%20SCA%20but%20the%20corresponding%20changes%20in%20humans%20have%20not%20been%20documented.%20In%20the%20present%20study%2C%20we%20used%2031-phosphorus%20magnetic%20resonance%20spectroscopy%20to%20investigate%20in%20vivo%20the%20metabolic%20changes%20induced%20by%20a%20moderate-intensity%20exercise%20in%20twelve%20SCA%20patients%2C%20eight%20sickle%20cell%20trait%20%28SCT%29%20carriers%2C%20and%20twelve%20controls%20women.%20The%20rest-exercise-recovery%20protocol%20disclosed%20slight%20differences%20regarding%20phosphocreatine%20%28PCr%29%20consumption%20and%20lactate%20accumulation%20between%20SCA%20patients%20and%20controls%20but%20these%20differences%20did%20not%20reach%20a%20statistical%20significance.%20On%20that%20basis%2C%20the%20in%20vivo%20metabolic%20changes%20associated%20with%20a%20moderate-intensity%20muscle%20exercise%20were%20slightly%20altered%20in%20SCA%20patients%20and%20SCT%20carriers%20but%20within%20a%20normal%20range.%20The%20present%20results%20strongly%20support%20the%20fact%20that%20a%20moderate-intensity%20exercise%20is%20safe%20and%20could%20be%20recommended%20in%20stable%20SCA%20patients%20and%20SCT%20subjects.NEW%20%26amp%3B%20NOTEWORTHY%20The%20main%20finding%20of%20the%20present%20study%20was%20that%20the%20metabolic%20changes%20associated%20with%20a%20moderate-intensity%20muscle%20exercise%20were%20slightly%20modified%20in%20stable%20sickle%20cell%20anemia%20patients%20and%20sickle%20cell%20trait%20carriers%20as%20compared%20to%20controls%20but%20still%20in%20the%20normal%20range.%20The%20present%20results%20strongly%20support%20the%20safety%20of%20a%20moderate-intensity%20exercise%20for%20stable%20sickle%20cell%20anemia%20patients%20and%20sickle%20cell%20trait%20carriers.%22%2C%22date%22%3A%222021-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1152%5C%2Fjapplphysiol.00790.2020%22%2C%22ISSN%22%3A%221522-1601%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227FK4UDH9%22%2C%22NW6SZQBR%22%2C%22HIWENPPK%22%2C%22ZP8JD3DQ%22%5D%2C%22dateModified%22%3A%222024-05-03T05%3A40%3A16Z%22%7D%7D%2C%7B%22key%22%3A%223P5PBZNS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Baboudjian%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBaboudjian%2C%20M.%2C%20Mhatli%2C%20M.%2C%20Bourouina%2C%20A.%2C%20Gondran-Tellier%2C%20B.%2C%20Anastay%2C%20V.%2C%20Perez%2C%20L.%2C%20Proye%2C%20P.%2C%20Lavieille%2C%20J.-P.%2C%20Duchateau%2C%20F.%2C%20Agostini%2C%20A.%2C%20Wazne%2C%20Y.%2C%20Sebag%2C%20F.%2C%20Foletti%2C%20J.-M.%2C%20Chossegros%2C%20C.%2C%20Raoult%2C%20D.%2C%20Touati%2C%20J.%2C%20Chagnaud%2C%20C.%2C%20Michel%2C%20J.%2C%20Bertrand%2C%20B.%2C%20Giovanni%2C%20A.%2C%20Radulesco%2C%20T.%2C%20Sartor%2C%20C.%2C%20Fournier%2C%20P.-E.%20and%20Lechevallier%2C%20E.%20%282021%29%20%26%23x201C%3BIs%20minor%20surgery%20safe%20during%20the%20COVID-19%20pandemic%3F%20A%20multi-disciplinary%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2C%2016%285%29%2C%20p.%20e0251122.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251122%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251122%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Is%20minor%20surgery%20safe%20during%20the%20COVID-19%20pandemic%3F%20A%20multi-disciplinary%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Baboudjian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Mhatli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adel%22%2C%22lastName%22%3A%22Bourouina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gondran-Tellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vassili%22%2C%22lastName%22%3A%22Anastay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Perez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Proye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Lavieille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Duchateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aubert%22%2C%22lastName%22%3A%22Agostini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Wazne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Sebag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Foletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrille%22%2C%22lastName%22%3A%22Chossegros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Raoult%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julian%22%2C%22lastName%22%3A%22Touati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justin%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baptiste%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Giovanni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Radulesco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Sartor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Edouard%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Lechevallier%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20To%20assess%20the%20risk%20of%20postoperative%20SARS-CoV-2%20infection%20during%20the%20COVID-19%20pandemic.%5CnMETHODS%3A%20The%20CONCEPTION%20study%20was%20a%20cohort%2C%20multidisciplinary%20study%20conducted%20at%20Conception%20University%20Hospital%2C%20in%20France%2C%20from%20March%2017th%20to%20May%2011th%2C%202020.%20Our%20study%20included%20all%20adult%20patients%20who%20underwent%20minor%20surgery%20in%20one%20of%20the%20seven%20surgical%20departments%20of%20our%20hospital%3A%20urology%2C%20digestive%2C%20plastic%2C%20gynecological%2C%20otolaryngology%2C%20gynecology%20or%20maxillofacial%20surgery.%20Preoperative%20self-isolation%2C%20clinical%20assessment%20using%20a%20standardized%20questionnaire%2C%20physical%20examination%2C%20nasopharyngeal%20RT-PCR%20and%20chest%20CT%20scan%20performed%20the%20day%20before%20surgery%20were%20part%20of%20our%20active%20prevention%20strategy.%20The%20main%20outcome%20was%20the%20occurrence%20of%20a%20SARS-CoV-2%20infection%20within%2021%20days%20following%20surgery.%20The%20COVID-19%20status%20of%20patients%20after%20discharge%20was%20updated%20during%20the%20postoperative%20consultation%20and%20to%20ensure%20the%20accuracy%20of%20data%2C%20all%20patients%20were%20contacted%20again%20by%20telephone.%5CnRESULTS%3A%20A%20total%20of%20551%20patients%20from%20six%20different%20specialized%20surgical%20Departments%20in%20our%20tertiary%20care%20center%20were%20enrolled%20in%20our%20study.%20More%20than%2099%25%20%28546%5C%2F551%29%20of%20included%20patients%20underwent%20a%20complete%20preoperative%20Covid-19%20screening%20including%20RT-PCR%20testing%20and%20chest%20CT%20scan%20upon%20admission%20to%20the%20Hospital.%20All%20RT-PCR%20tests%20were%20negative%20and%20in%2012%20cases%20%282.2%25%29%2C%20preoperative%20chest%20CT%20scans%20detected%20pulmonary%20lesions%20consistent%20with%20the%20diagnosis%20criteria%20for%20COVID-19.%20No%20scheduled%20surgery%20was%20postponed.%20One%20patient%20%280.2%25%29%20developed%20a%20SARS-CoV-2%20infection%2020%20days%20after%20a%20renal%20transplantation.%20No%20readmission%20or%20COVID-19%20-related%20death%20within%2030%20days%20from%20surgery%20was%20recorded.%5CnCONCLUSIONS%3A%20Minor%20surgery%20remained%20safe%20in%20the%20COVID-19%20Era%2C%20as%20long%20as%20all%20appropriate%20protective%20measures%20were%20implemented.%20These%20data%20could%20be%20useful%20to%20public%20Health%20Authorities%20in%20order%20to%20improve%20surgical%20patient%20flow%20during%20a%20pandemic.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0251122%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A44Z%22%7D%7D%5D%7D
Gavoille, A., Leray, E., Marignier, R., Rollot, F., Casey, R., Mathey, G., Michel, L., De Seze, J., Ciron, J., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Laplaud, D.A., Papeix, C., Defer, G., Moreau, T., Berger, E., Dubessy, A.-L., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al Khedr, A., Casez, O., Bourre, B., Wahab, A., Magy, L., Camdessanche, J.-P., Doghri, I., Moulin, S., Labeyrie, C., Hankiewicz, K., Dos Santos, A., Pottier, C., Manchon, E., Tchikviladze, M., Lebrun-Frenay, C., Vukusic, S. and OFSEP investigators (2025) “Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis,” Neurology, 105(4), p. e213907. Available at: https://doi.org/10.1212/WNL.0000000000213907.
Robin, C., Rollot, F., Lefort, M., Casey, R., Vukusic, S., Mathey, G., Ciron, J., De Seze, J., Stankoff, B., Maillart, E., Ruet, A., Labauge, P.M., Kwiatkowski, A., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Casez, O., Bourre, B., Wahab, A., Magy, L., Moulin, S., Camdessanche, J.-P., Doghri, I., Sarov, M., Hankiewicz, K., Pottier, C., Dos Santos, A., Manchon, E., Tchikviladze, M., Nifle, C., Kerbrat, A., Edan, G., Le Page, E., Michel, L. and as the OFSEP Investigators (2025) “Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis,” Neurology, 105(3), p. e213744. Available at: https://doi.org/10.1212/WNL.0000000000213744.
Hong, J., Gaubert, M., Lefort, M., Ferré, J.C., Le Page, E., Michel, L., Labauge, P., Pelletier, J., de Seze, J., Durand-Dubief, F., Cotton, F., Edan, G., Bannier, E., Combès, B. and Kerbrat, A. (2025) “Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up,” Journal of Neurology, 272(4), p. 316. Available at: https://doi.org/10.1007/s00415-025-13068-2.
Mainguy, M., Casey, R., Vukusic, S., Lebrun-Frenay, C., Berger, E., Kerbrat, A., Al Khedr, A., Bourre, B., Ciron, J., Clavelou, P., De Seze, J., Defer, G., Doghri, I., Dos Santos, A., Hankiewicz, K., Labauge, P.M., Le Page, E., Magy, L., Maillart, E., Manchon, E., Michel, L., Moreau, T., Moulin, S., Pelletier, J., Pottier, C., Ruet, A., Sarov, M., Stankoff, B., Thouvenot, E., Wahab, A., Zephir, H., Leray, E. and Laplaud, D.A. (2025) “Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200371. Available at: https://doi.org/10.1212/NXI.0000000000200371.
de Sèze, J., Labauge, P., Liblau, R., Martinez, M., Moreau, T., Suchet, L., Vermersch, P., Vukusic, S., Mathey, G., Michel, L., Ciron, J., Ruet, A., Maillart, E., Zephir, H., Papeix, C., Defer, G., Cohen, M., Laplaud, D.A., Berger, E., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Giannesini, C., Casez, O., Bourre, B., Wahab, A., Magy, L., Camdessanché, J.-P., Doghri, I., Labeyrie, C., Hankiewicz, K., Neau, J.-P., Pottier, C., Dobay, P., Li, H., Levin, S., Gros, M., Ruiz, M. and Rollot, F. (2025) “LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France,” Advances in Therapy [Preprint]. Available at: https://doi.org/10.1007/s12325-024-03092-5.
Martin, S., André, R., Trabelsi, A., Michel, C.P., Fortanier, E., Attarian, S., Guye, M., Dubois, M., Abdeddaim, R. and Bendahan, D. (2025) “Importance of neural network complexity for the automatic segmentation of individual thigh muscles in MRI images from patients with neuromuscular diseases,” Magma (New York, N.Y.) [Preprint]. Available at: https://doi.org/10.1007/s10334-024-01221-3.
Comino Garcia Muñoz, A., Marfouk, O., Michel, C.P., Varlet, I., Royer, E., Perles-Barbacaru, T.-A. and Viola, A. (2025) “Characterization of experimental cerebral malaria by volumetric MRI A comparative study across the sexes,” PloS One, 20(8), p. e0328693. Available at: https://doi.org/10.1371/journal.pone.0328693.
Fortanier, E., Michel, C.P., Hostin, M.A., Delmont, E., Verschueren, A., Guye, M., Bellemare, M.-E., Bendahan, D. and Attarian, S. (2025) “Quantitative muscle MRI combined with AI-based segmentation as a follow-up biomarker for ATTRv patients: A longitudinal pilot study,” European Journal of Neurology, 32(1), p. e16574. Available at: https://doi.org/10.1111/ene.16574.
Cruz, E.S., Fortanier, E., Michel, C.P., Delmont, E., Verschueren, A., Hostin, M.-A., Bendahan, D. and Attarian, S. (2025) “Intraepineurial Fat Fraction: A Novel MR Neurography-Based Biomarker in Transthyretin Amyloidosis Polyneuropathy,” European Journal of Neurology, 32(4). Available at: https://doi.org/10.1111/ene.70168.
Hay, M., Rollot, F., Casey, R., Kerbrat, A., Edan, G., Mathey, G., Labauge, P., De Sèze, J., Vukusic, S., Laplaud, D.-A., Papeix, C., Moreau, T., Thouvenot, E., Defer, G., Lebrun-Frénay, C., Ciron, J., Berger, E., Stankoff, B., Clavelou, P., Maillart, E., Heinzlef, O., Zéphir, H., Ruet, A., Casez, O., Moulin, S., Al-Khedr, A., Bourre, B., Pelletier, J., Magy, L., Neau, J.-P., Camdessanché, J.-P., Doghri, I., Wahab, A., Tchikviladzé, M., Labeyrie, C., Hankiewicz, K., Le Page, E., Michel, L. and as the OFSEP Investigators (2024) “Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study,” Neurology, 103(8), p. e209886. Available at: https://doi.org/10.1212/WNL.0000000000209886.
Fortanier, E., Hostin, M.A., Michel, C., Delmont, E., Bellemare, M.-E., Guye, M., Bendahan, D. and Attarian, S. (2024) “One-Year Longitudinal Assessment of Patients With CMT1A Using Quantitative MRI,” Neurology, 102(9), p. e209277. Available at: https://doi.org/10.1212/WNL.0000000000209277.
Monestier, L., Del Grande, J., Haddad, R., Santini, L., Michel, J., Varoquaux, A. and Fakhry, N. (2024) “Correlation between MRI (DWI and DCE) and cellularity of parotid gland pleomorphic adenomas,” European Archives of Oto-Rhino-Laryngology, 281(5), pp. 2655–2665. Available at: https://doi.org/10.1007/s00405-024-08562-8.
Michel, C.P., Messonnier, L.A., Giannesini, B., Vilmen, C., Sourdon, J., Le Fur, Y. and Bendahan, D. (2024) “Endurance training and hydroxyurea have synergistic effects on muscle function and energetics in sickle cell disease mice,” Blood Cells, Molecules & Diseases, 107, p. 102853. Available at: https://doi.org/10.1016/j.bcmd.2024.102853.
Jouvenot, G., Courbon, G., Lefort, M., Rollot, F., Casey, R., Le Page, E., Michel, L., Edan, G., de Seze, J., Kremer, L., Bigaut, K., Vukusic, S., Mathey, G., Ciron, J., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Stankoff, B., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al-Khedr, A., Casez, O., Bourre, B., Cabre, P., Wahab, A., Magy, L., Camdessanché, J.-P., Doghri, I., Moulin, S., Ben-Nasr, H., Labeyrie, C., Hankiewicz, K., Neau, J.-P., Pottier, C., Nifle, C., Collongues, N., Kerbrat, A. and OFSEP Investigators (2024) “High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS,” JAMA neurology, p. e240395. Available at: https://doi.org/10.1001/jamaneurol.2024.0395.
White, M.S., Ogier, A.C., Chenevert, T.L., Zucker, E., Stoneback, L., Michel, C.P., Palmieri-Smith, R.M. and Lepley, L.K. (2024) “Beyond weakness: Exploring intramuscular fat and quadriceps atrophy in ACLR recovery,” Journal of Orthopaedic Research, 42(11), pp. 2485–2494. Available at: https://doi.org/10.1002/jor.25910.
Guenoun, D., Wirth, T., Roche, D., Michel, C.P., Daudé, P., Ogier, A.C., Chagnaud, C., Mattei, J.P., Pini, L., Guye, M., Ollivier, M., Bendahan, D. and Guis, S. (2023) “Ultra-high field magnetic resonance imaging of the quadriceps tendon enthesis in healthy subjects,” Surgical and Radiologic Anatomy, 45(8), pp. 1049–1054. Available at: https://doi.org/10.1007/s00276-023-03175-y.
Brocard, G., Casey, R., Dufay, N., Marignier, R., Michel, L., Hisbergues, M., Ayrignac, X., Lehmann, S., Thouvenot, E., Gallot, G., Collongues, N., Herpe, Y.-E., Lebrun-Frenay, C., Cotton, F., De Sèze, J., Guillemin, F., Moreau, T., Pelletier, J., Stankoff, B., Vukusic, S., Zephir, H., Laplaud, D. and OFSEP investigators and biobanks (2023) “The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers,” Multiple Sclerosis and Related Disorders, 77, p. 104872. Available at: https://doi.org/10.1016/j.msard.2023.104872.
Sabathé, C., Casey, R., Vukusic, S., Leray, E., Mathey, G., De Sèze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., Zéphir, H., Michel, L., Lebrun-Frenay, C., Moisset, X., Thouvenot, E., Camdessanché, J.-P., Bakchine, S., Stankoff, B., Al Khedr, A., Cabre, P., Maillart, E., Berger, E., Heinzlef, O., Hankiewicz, K., Moreau, T., Gout, O., Bourre, B., Wahab, A., Labauge, P., Montcuquet, A., Defer, G., Maurousset, A., Maubeuge, N., Dimitri Boulos, D., Ben Nasr, H., Nifle, C., Casez, O., Laplaud, D.-A. and Foucher, Y. (2023) “Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system,” Multiple Sclerosis Journal, 29(2), pp. 236–247. Available at: https://doi.org/10.1177/13524585221139156.
Michel, C.P., Bendahan, D., Giannesini, B., Vilmen, C., Le Fur, Y. and Messonnier, L.A. (2023) “Effects of hydroxyurea on skeletal muscle energetics and force production in a sickle cell disease murine model,” Journal of Applied Physiology, 134(2), pp. 415–425. Available at: https://doi.org/10.1152/japplphysiol.00333.2022.
Vukusic, S., Marignier, R., Ciron, J., Bourre, B., Cohen, M., Deschamps, R., Guillaume, M., Kremer, L., Pique, J., Carra-Dalliere, C., Michel, L., Leray, E., Guennoc, A.-M., Laplaud, D., Androdias, G., Bensa, C., Bigaut, K., Biotti, D., Branger, P., Casez, O., Daval, E., Donze, C., Dubessy, A.-L., Dulau, C., Durand-Dubief, F., Hebant, B., Kwiatkowski, A., Lannoy, J., Maarouf, A., Manchon, E., Mathey, G., Moisset, X., Montcuquet, A., Roux, T., Maillart, E. and Lebrun-Frenay, C. (2023) “Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society,” Multiple Sclerosis Journal, 29(1), pp. 37–51. Available at: https://doi.org/10.1177/13524585221130934.
Vukusic, S., Carra-Dalliere, C., Ciron, J., Maillart, E., Michel, L., Leray, E., Guennoc, A.-M., Bourre, B., Laplaud, D., Androdias, G., Bensa, C., Bigaut, K., Biotti, D., Branger, P., Casez, O., Cohen, M., Daval, E., Deschamps, R., Donze, C., Dubessy, A.-L., Dulau, C., Durand-Dubief, F., Guillaume, M., Hebant, B., Kremer, L., Kwiatkowski, A., Lannoy, J., Maarouf, A., Manchon, E., Mathey, G., Moisset, X., Montcuquet, A., Pique, J., Roux, T., Marignier, R. and Lebrun-Frenay;, C. (2023) “Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society,” Multiple Sclerosis Journal, 29(1), pp. 11–36. Available at: https://doi.org/10.1177/13524585221129472.
Durelle, C., Delmont, E., Michel, C., Trabelsi, A., Hostin, M.-A., Ogier, A., Bendahan, D. and Attarian, S. (2023) “Quantification of muscle involvement in familial amyloid polyneuropathy using MRI,” European Journal of Neurology, 30(10), pp. 3286–3295. Available at: https://doi.org/10.1111/ene.15970.
Hostin, M.-A., Ogier, A.C., Michel, C.P., Le Fur, Y., Guye, M., Attarian, S., Fortanier, E., Bellemare, M.-E. and Bendahan, D. (2023) “The Impact of Fatty Infiltration on MRI Segmentation of Lower Limb Muscles in Neuromuscular Diseases: A Comparative Study of Deep Learning Approaches,” Journal of Magnetic Resonance Imaging, 58(6), pp. 1826–1835. Available at: https://doi.org/10.1002/jmri.28708.
Demuth, S., Guillaume, M., Bourre, B., Ciron, J., Zephir, H., Sirejacob, Y., Kerbrat, A., Lebrun-Frenay, C., Papeix, C., Michel, L., Laplaud, D., Vukusic, S., Maillart, E., Cohen, M., Audoin, B., Marignier, R., Collongues, N. and NOMADMUS Study Group (2022) “Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study,” Journal of Neuroinflammation, 19(1), p. 62. Available at: https://doi.org/10.1186/s12974-022-02420-2.
Trojani, M.-C., Chorin, F., Gerus, P., Breuil, V., Michel, C., Guis, S., Bendahan, D. and Roux, C. (2022) “Concentric or eccentric physical activity for patients with symptomatic osteoarthritis of the knee: a randomized prospective study,” Therapeutic Advances in Musculoskeletal Disease, 14, p. 1759720X221102805. Available at: https://doi.org/10.1177/1759720X221102805.
Michel, C.P., Messonnier, L.A., Giannesini, B., Chatel, B., Vilmen, C., Le Fur, Y. and Bendahan, D. (2022) “Effects of Hydroxyurea on Skeletal Muscle Energetics and Function in a Mildly Anemic Mouse Model,” Frontiers in Physiology, 13, p. 915640. Available at: https://doi.org/10.3389/fphys.2022.915640.
Sarlon-Bartoli, G., Michel, Q., Sarlon, E., Carcopino-Tusoli, M., Suchon, P., Soler, R., Bartoli, M.A., Brunet, D., Morange, P. and Charbonnier, A. (2021) “Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia,” Journal De Medecine Vasculaire, 46(2), pp. 66–71. Available at: https://doi.org/10.1016/j.jdmv.2021.02.002.
Chatel, B., Bernit, E., Vilmen, C., Michel, C., Bendahan, D. and Messonnier, L.A. (2021) “In vivo muscle function and energetics in women with sickle cell anemia or trait: a 31P-magnetic resonance spectroscopy study,” Journal of Applied Physiology (Bethesda, Md.: 1985), 130(3), pp. 737–745. Available at: https://doi.org/10.1152/japplphysiol.00790.2020.
Baboudjian, M., Mhatli, M., Bourouina, A., Gondran-Tellier, B., Anastay, V., Perez, L., Proye, P., Lavieille, J.-P., Duchateau, F., Agostini, A., Wazne, Y., Sebag, F., Foletti, J.-M., Chossegros, C., Raoult, D., Touati, J., Chagnaud, C., Michel, J., Bertrand, B., Giovanni, A., Radulesco, T., Sartor, C., Fournier, P.-E. and Lechevallier, E. (2021) “Is minor surgery safe during the COVID-19 pandemic? A multi-disciplinary study,” PloS One, 16(5), p. e0251122. Available at: https://doi.org/10.1371/journal.pone.0251122.